{"title": "PDF", "author": "PDF", "url": "https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Zervixkarzinom_Praevention/S3LL_EvidenceReport_Modeling_SroczynskiAndSiebert.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \nEVIDENCE REPORT  \nDecision Analysis for the Evaluation of Benefits, Harms and Cost -effectiveness \nof Different Cervical Cancer Screening Strategies to Inform the S3 Clinical \nGuideline \u201cPrevention of Cervical Cancer\u201d in the Context of the German \nHealth Care System  \n \n \nAss.-Prof. Dr. Gaby Sroczynski, M.P.H.,  \nUniv.- Prof. Dr. Uwe Siebert, M.P.H., M .Sc. \n \nInstitute of Public Health, Medical Decision Making and Health Technology Assessment ,  \nDepartment of Public Health, Health Services Research and Health Technology  Assessment,  \nUMIT - University for Health Sciences, Medical Informatics and Technology  \nEduard- Walln\u00f6fer- Zentrum  1, 6060 Hall i.T., Austria \n \n \n \n  \nJanuary 2016  \n  2  \nTable of Contents  \n1 List of Tables  .................................................................................................................... 4 \n2 List of Figures  ................................................................................................................... 5 \n3 Introduction ..................................................................................................................... 7 \n4 Methods  .......................................................................................................................... 7 \n4.1 Overview  ................................................................................................................................ 7 \n4.2 Model Design and Framework  ............................................................................................... 7 \n4.2.1  Model Type and Simulation Technique  .............................................................................. 7 \n4.2.2  Time Horizon and Cycle Length .......................................................................................... 8 \n4.2.3  Perspective  ......................................................................................................................... 8 \n4.2.4  Discounting ........................................................................................................................ 8 \n4.2.5  Outcomes  ........................................................................................................................... 8 \n4.2.6  Natural History Model Structure ........................................................................................ 9 \n4.3 Screening and Follow -up Strategies  ..................................................................................... 12 \n4.3.1  Primary Screening Strategies  ........................................................................................... 12 \n4.4 Model Input Parameters  ...................................................................................................... 16 \n4.4.1  Disease Progression  ......................................................................................................... 16 \n4.4.2  Population Characteristics  ............................................................................................... 18 \n4.4.3  Screening Adherence  ....................................................................................................... 18 \n4.4.4  Screening Test Characteristics  ......................................................................................... 18 \n4.4.5  Resource Utilization and Cost Data  ................................................................................. 20 \n4.5 Model Application and Analyses  .......................................................................................... 23 \n4.5.1  Calibration  ....................................................................................................................... 23 \n4.5.2  Validation ......................................................................................................................... 23 \n4.5.3  Benefit -Harm Analysis  ..................................................................................................... 24 \n4.5.4  Cost -Effectiveness Analysis  .............................................................................................. 25 \n4.5.5  Sensitivity Analyses  .......................................................................................................... 26 \n5 Results  ............................................................................................................................27  \n5.1 Screening- Related Benefits  .................................................................................................. 27 \n5.1.1  Reduction in Cervical Cancer Incidence  ........................................................................... 27 \n5.1.2  Reduction in Cervical Cancer Mortality ............................................................................ 28 \n5.1.3  Gains in Remaining Life Expectancy  ................................................................................ 30 \n5.2 Screening- Related Harms  ..................................................................................................... 32 3 5.2.1  Total Number of Positive Screening Test Results  ............................................................. 32 \n5.2.2  Total Number of Colposcopies  ......................................................................................... 34 \n5.2.3  Total Number of Conizations  ........................................................................................... 35 \n5.2.4  Total Number of Conizations < CIN3  ................................................................................ 37 \n5.3 Benefit -Harm Balance  .......................................................................................................... 38 \n5.3.1  Benefit -Harm Analyse s Using Screening Test Positive Results as Harm Outcome  .......... 38 \n5.3.2  Benefit -Harm Analyses Using Colposcopies as Harm Outcome  ....................................... 42 \n5.3.3  Benefit -Harm Analyses Using Conization < CIN3 as Harm Outcome  ............................... 45 \n5.4 Incremental Cost -Effectiveness  ........................................................................................... 49 \n6 Results: Sensi tivity Analyses  ............................................................................................53  \n6.1 Benefit -Harm Balance  .......................................................................................................... 53 \n6.1.1  Screening Test -Positive Results ........................................................................................ 53 \n6.1.2  Colposcopies  .................................................................................................................... 59 \n6.1.3  Conization < CIN3  ............................................................................................................. 65 \n6.2 Incremental Cost -Effectiveness  ........................................................................................... 71 \n7 Discussion of Model Features and Limitations  ..................................................................78  \n8 References  ......................................................................................................................81  \n \n  4 1 List of Tables  \nTable 1. Natural history model parameters  .......................................................................................... 17 \nTable 2. Age -specific screening adherence  ........................................................................................... 18 \nTable 3. Model parameters: screening test characteristics  .................................................................. 19 \nTable 4. Test accuracy data of secondary tests (triage)  ........................................................................ 20 \nTable 5. Aggregated costs (per unit) for screening, diagnostic wo rk-up, therapy, and follow -up \nprocedures (Index year 2014).  .............................................................................................................. 22 \nTable 6. Reduction in cervical cancer incidence  .................................................................................... 28 \nTable 7. Reduction in cervical cancer mortality  .................................................................................... 30 \nTable 8. Remaining life expectancy  ....................................................................................................... 32 \nTable 9. Total number of positive screening t est results  ...................................................................... 33 \nTable 10. Total number of colposcopies  ............................................................................................... 35 \nTable 11. Total number of conizations  .................................................................................................. 36 \nTable 12. Total number of conizations < CIN 3 ...................................................................................... 38 \nTable 1 3. Base -case results: discounted total costs, effects, and incremental cost- effectiveness ratios\n ............................................................................................................................................................... 51 \nTable 14. Sensitivity analysi s IHBR (positive tests/LYG): decreased cytology sensitivity.  ..................... 54 \nTable 15 . Sensitivity analysis IHBR (positive tests/LYG): alternative sensitivity and specificity values for \ncolposcopy.  ............................................................................................................................................ 56 \nTable 16. Sen sitivity analysis IHBR (positive tests/LYG): 100% screening adherence.  .......................... 58 \nTable 17. Sensitivity analysis IHBR (colposcopies/LYG):  decreased cytology sensitivity.  ..................... 60 \nTable 18. Sensitivity analysis IHBR (colposcopies/LYG): alternative sensitivity and specificity values for \ncolposcopy.  ............................................................................................................................................ 62 \nTable 19. Sensitivity analysis IHBR (colposcopies/LYG): decreased cytology sensitivity.  ..................... 64 \nTable 20. Sensitivity analysis IHBR (conizations < CIN3/LYG): decreased cytology sensitivity.  ............ 66 \nTable 21. Sensitivity analysis IHBR (conizations < CIN3/LYG): alternative sensitivity and specificity values for colposcopy.  ........................................................................................................................... 68 \nTable 22. Sensitivity analysis IHBR (conizations < CIN3/LYG): 100% screening adherence.  ................. 70 \nTable 23. Sensitivity analysis: decreased cytology sensitivity.  .............................................................. 72 \nTable 24. Sensitivity analysis: alternative colposcopy accuracy data.  .................................................. 74 \nTable 25. Sensitivity analysis: 100% screening adherenc e. ................................................................... 75 \nTable 26. Sensitivity analysis: cancer treatment costs increased to 4 -fold of the base case values.  ... 77 \n \n  5 2 List of Figures  \nFigure 1. State -transition diagram of the natural history Markov model structure of the German \ncervical cancer screening model  ........................................................................................................... 11 \nFigure 2. Screening - and follow -up algorithms (in German)  .................................................................  14 \nFigure 3. Illustration of the benefit -harm frontier concept  .................................................................. 25 \nFigure 4. Cost -Effectiveness Frontier ..................................................................................................... 26 \nFigure 5. Benefit -harm frontier: Reduction in cervical cancer cases versus total number primary \nscreening test- positive results  ............................................................................................................... 39 \nFigure 6. Benefit -harm frontier: Reduction in cervical cancer mortality versus total number primary \nscreening test- positive results  ............................................................................................................... 40 \nFigure 7. Benefit -harm frontier: Life -years gained versus total number primary screening test -positive \nresults  .................................................................................................................................................... 41 \nFigure 8. Benefit -harm frontier: Reduction in cervical cancer cases versu s total number colposcopies\n ............................................................................................................................................................... 42 \nFigure 9. Benefit -harm frontier: Reduction in cervical cancer mortality versus total number \ncolposc opies  .......................................................................................................................................... 44 \nFigure 10. Benefit -harm frontier: Life -years gained versus total number colposcopies  ....................... 45 \nFigure 11. Benefit -harm frontier: Reduction in cervical cancer cases versus total number conizations < \nCIN 3  ...................................................................................................................................................... 46 \nFigure 12. Benefit -harm frontier: Reduction in cervical cancer mortality versus total number \nconizations < CIN 3  ................................................................................................................................ 47 \nFigure 13. Benefit -harm frontier: Life -years gained versus total number conizations < CIN 3  ............. 49 \nFigure 14. Base -case results: cost -effectiveness frontier  ...................................................................... 52 \nFigure 15. Sens itivity analysis IHBR (positive tests/LYG): decreased sensitivity values for cytology  .... 55 \nFigure 16 . Sensitivity analysis IHBR (positive tests/LYG): alternative sensitivity and specificity values \nfor colposcopy  ....................................................................................................................................... 57 \nFigure 17. Sens itivity analysis IHBR (positive tests/LYG): 100% screening adherence.  ........................ 59 \nFigure 18. Sensitivity analysis IHBR (colposcopies/LYG): decreased sensitivity values for cytology  .... 61 \nFigure 19. Sensitivity analysis IHBR (colposcopies/LYG): alternative sensitivity and specificity values \nfor colposcopy.  ...................................................................................................................................... 63 \nFigure 20. Sensitivity analysis IHBR (colposcopies/LYG): 100% screening adherence  .......................... 65 \nFigure 21. Sensitivity analysis IHBR (conizations < CIN3/LYG): decreased sensitivity values for \ncytology.  ................................................................................................................................................ 67 \nFigure 22. Sensitivity analysis: alternative sensitivity and specificity values for colposcopy ................ 69 \nFigure 23. Sensitivity analysis IHBR (conizations < CIN3/LYG): 100% screening adherence  ................. 71 \nFigure 24. Sensitivity analysis: decreased sensitivity values for cytology  ............................................. 73 \nFigure 25. Sensitivity analysis: alternative sensitivity and specificity values for colposcopy ................ 74 \nFigure 26. Sensitivity analysis: 100% screening adherence.  .................................................................  76 \nFigure 27. Sensitivity analysis: increased cancer treatment costs  ........................................................ 77 6  7 3 Introduction  \nThis document describes the methods and results of the decision -analytic study  for cervical cancer \nscreening to evaluate the benefits, harms and cost -effectiveness of different scr eening strategies in \norder to inform the development of the German evidence -based S3 clinical g uideline  \u201cPrevention of \nCervical Cancer \u201d (AWMF registration number 015 -  027OL) .  \n4 Methods  \n4.1 Overview  \nWe performed  an evidence -based  benefit -harm analysis and cost -effectiveness analysis comparing \nseveral cervical cancer screening strategies . In order to synthesize all best available evidence, we \nperformed a decision analysis incorporating current evidence on epidemiologic parameters, benefits, \nharms and costs  (1). \nThe decision -analytic model is designed to be applied in the context of comparative effectiveness \nanalysis and economic evaluation analysis in order to inform evidence -based clinical guideline \ndevelopment. The design of the model follows international st andards of decision -analytic modeling, \nsuch as the ISPOR -SMDM Joint Task Force Modeling Good Research Practices (2-5) and international \nkey principles for health technology assessment  (HTA)  (6, 7 ). \n4.2 Model Design and Framework  \n4.2.1 Model Type and Simulation Technique  \nWe developed a decision -analytic Markov state- transition model for the long- term natural history of \ncervical cancer development including human papillomavirus ( HPV ) infection, pre -invasive cancer, \ninvasive cancer, and death . Different screening strategies and follow -up management and treatment \nalgorithms based on the algorithms discussed in the S3  clinical guideline process have been \nimplemented in the model structure.  \nThe model was based on prior health technology assessments (HTA) and previously published and \nvalidated models for the German health care context (8-11) and was adapted , updated and extended 8 to the research questi ons of this project . The application of the model allows for estimating the long -\nterm clinical and economic consequences ( i.e., benefits, harms and costs) of different screening \nstrategies in the context of the German health care system . As the number of h ealth states in this \nmodel is manageable, the model is designed for a Markov cohort simulation  (4, 5).  \n4.2.2 Time Horizon and Cycle Length  \nIn order to capture all relevant clinical and economic events, a life-long time horizon was applied for \nall analyses . The Mark ov model has a cycle length of one  year.  \n4.2.3 Perspective  \nThe per spective of the German health care system was adopted to assess t he consequences of the \nevaluated screening strategies .  \n4.2.4 Discounting \nFor the cost -effectiveness -analys is, all outcomes are discounted. According to  the recommendations  \nfor health economic evaluations in the general methods guidelines of the Institute for Quality and \nEfficiency in Health Care (IQWiG ), the discount rate for the base -case analysis is set to 3 % for the \nhealth effects and for costs  (12). \n4.2.5 Outcomes  \nFor each examined strategy, the following outcomes are projected : (1) reduction in cervical cancer \nincidence , (2) reduction in cervical cancer mortality, (3) remaining life expectancy, (4) total number of \nscreen -positive test results  (with sc heduled re -visit within one year or immediate colposcopy) , (5) \ntotal number of colposcopies,  (6) total number of conizations, (7 ) unnecessary conizations  (defined \nas conizations  of low or moderate grade cervical cell lesions), (8) lifetime costs,  (9) incre mental harm -\nbenefit ratio s (IHBR) expressed in units of additional harm per additional benefit , (9) discounted \nincremental cost -effectiveness ratios (ICER) expressed as Euros per life -year gained ( Euro/ LYG).  9 4.2.6 Natural History Model Structure  \nThe model reflec ts the natural history of cervical cancer development . A cohort of 15 year -old \nhealthy women not vaccinated against HPV 16/18 enters the model and may move over their lifetime \nthrough different health states based on the natural history of cervical cancer  development . In the \nMarkov model,  time is divided in annual cycles . \nWomen can be infected with a high -risk HPV  that may be cleared or not. We did not consider \nheterogeneity of the population with respect to infection with different high -risk HPV -types. We \nneither considered an infection with a low -risk HPV, as these HPV types are considered not to \nrepresent a significant risk for cervical cancer. Persistent HPV infection is associated with a high risk \nfor developing precancerous  lesions of the cervix, so ca lled cervical intraepithelial neoplasia (CIN) . \nPrecancerous lesions could regress , persist  or may  progress to a more severe stage  and finally into \ninvasive cervical cancer. Invasive cervical cancer is categorized in stages I  to IV according to the \nstagin g system of the F\u00e9d\u00e9ration Internationale de Gyn\u00e9 cologie et d'Obst\u00e9trique ( FIGO ). Regression \nof invasive cervical cancer to precancerous lesions was not considered . As precancerous lesions \nusually do not cause any symptoms, it was assumed that they could be detected by screening only, \nwhereas invasive cancer cases could be detected by the onset of symptoms and/ or screening. \nDetected p recancerous lesions and invasive cancer were assumed to be treated according to the \nGerman  treatment guidelines. Women treated for precancerous lesions were assumed to return to \nthe healthy sta te (no HPV -infection and no lesion) and be at a normal risk for future high -risk HPV \ninfection and disease. Women treated for invasive cervical cancer were assumed to have higher risk \nto die  than women without cervical cancer based on FIGO -specific survival rates . However, we \nassumed equal mortality rates for women with cervical cancer who were tumor -free six years after \ntreatment  (cancer survivor s) compared with women without cervical cancer. Women of all ages may \ndie from other cause s than cervical cancer due to age - and gender -specific mortality . We assumed \nthat women who undergo a hysterectomy because of other reasons than  cervical cancer  or CIN  are \nno longer at  risk for cervical cancer an d leave the screening population . \nOver time  and for each screening strategy , the model assesses outcomes such as cervical cancer \ncases and deaths, clinical events, remaining life  expectancy, and cost s. \nFigure 1 shows a simplified state- transition diagram of the natural history Markov model structure. \nScreening strategies are implemented as specific decision strateg ies. All screening strategies  have the \nsame basic structure concerning the natural history. Screening- specific pathways  are implemented as \nMarkov cycle trees. Screening -specific d ifferences are indicated by locally assigned values for 10 variables (e.g., screening test sensitivity and specificity, screening interval, costs) at each screening \nstrategy branch.  \n Figure 1. State -transition diagram of the natural history Markov model structure of the German  cervical cancer screening model  \n \nCIN: cervical intraepithelial neoplasia, CIS: c arcinoma in situ, Diag.: d iagnosed cervical cancer, FIGO: cervical can cer stage classification F\u00e9d\u00e9ration \nInternationale de Gyn\u00e9 cologie et d'Obst\u00e9trique, HPV: h uman papillomavirus, NL: no lesion, Undiag.: undiagnosed cervical cancer.  \n \n12 4.3 Screening and Follow -up Strategies  \n4.3.1 Primary Screening Strategies  \nThe evidence -based decisio n-analytic  model compares several different screening strategies that \ndiffer by screening interval, primary screening test( -combinations), and follow -up management \nalgorithms.  \nIn accordance with the S3  clinical guidelines,  in the base -case analysis of our model , cervical cancer \nscreening should start at age 25  years, with no upper age limit for the end of screening.   \nThe model compares 33 different primary screening strategies (including no screening) that differ by \ninitial screening test or test combinati ons, by follow -up algorithms, screening interval and age at \nwhich a primary screening test is applied.  \nIn the model, the following screening strategies  are assessed : (1.) no screening; (2.) annual Pap \ncytology in women aged 20 years and older with current  recommended follow -up algorithm  (for \ncomparison purposes) ; (3.-6.) Pap cytology alone in women aged 25 years and older in intervals of \none, two, three or five years with p16/Ki -67 dual stain triage ; (7.-10.) Pap cytology alone in women \naged 25 years and o lder in intervals of one, two, three or five years with HPV triage ; (11. -14.) liquid \nbased cytology (LBC) alone in women aged 25 years and older in intervals of one, two, three or five \nyears with p16/Ki- 67 dual stain triage; ( 15.-18.) LBC cytology alone in  women aged 25 years and older \nin intervals of one, two, three or five years with HPV triage;  (19.-21.) cotesting with HPV and Pap \ncytology in women older than 30 years in intervals of two, three or five years, and biennial Pap \ntesting in women aged 25 to 30 years; (22. -24.) cotesting with HPV and LBC cytology in women older \nthan 30 years in intervals of two, three or five years, and biennial Pap testing in women aged 25 to 30 \nyears; (25. -27.) HPV testing with Pap -cytology triage for HPV -positive women in w omen older than  30 \nyears and older, in intervals of two, three or five years and biennial Pap testing in women aged 25 to \n30 years ; (28. -30.) HPV testing with LBC -cytology triage for HPV -positive women in women older than \n30 years and older, in intervals o f two, three or five years and biennial Pap testing in women aged 25 \nto 30 years;  (31.-33.) HPV testing with p16/Ki -67 dual -stain triage for HPV -positive women in women \nolder than  30 years, in intervals of two, three or five years and biennial Pap testing in women aged 25 \nto 30 years.  13 Figure 2 shows a flow -chart diagram of the screening strategies with the respective follow -up \nalgorithms.  \nClinical practice data were derived from current guidelines for cervical cance r diagnosis , \nmanagement and treatment  of pre -invasive lesions and invasive cancer in Germany . In the model, \ndiagnostic work -up and treatment procedures for histologically diagnosed preinvasive cervical lesions \nand invasive cancer are the same for all scree ning strategies being evaluated.  \n  \n14 Figure 2. Screening - and follow -up algorithms  (in German)  \n \n \n15  \nKo-Testung in 12 Monaten: Kontrolle mit HPV + Zytologie  in 12 Monaten  \n \n \n \n16 4.4 Model Input P arameters  \nModel parameters are  presented as mea ns. Uncertainty is expressed in 95% confidence \nintervals (95% CI) or ranges.  \n4.4.1 Disease Progression  \nThe natural history of cervical cancer development was defined by annual transition \nprobabilities for the progression or regression from a specific health stat e to another health \nstate of the disease. All natural history parameter values are evidence -based and were \nderived from the  published  literature (13-25)) and calibrated (10, 11, 26)  to fit specific \nepidemiologic data observed in an unscreened population in Germany  (see Table 1). \nAge-specific rates for benign hysterectomy were 0.884% for age 35 -39 years, 1.125% for 40 -\n44 years, 1.074% for 45- 49 years , and 0.597% for age 50 years and older (25) . Stage -specific \nannual cervical cancer mortality rates were based on original data from the Munich Cancer \nRegistry (MCR) for the years 1988 -2006. Based on these data, five- year survival rates for \nFIGO I, II, III, and IV were 94.2%, 73.5%, 42.0%, and 27.7%, respectively. Women could die \nfrom causes other than cervical cancer according to German age -specific all- cause mortality \nrates for females using German life tables from 2009/2011 from the German Federal \nStatistical Office (27). These age- specific mortality rates were reduced by the age -specific \ncervical cancer mortality derived from the German Federal Statistical Office  in order  to \nadjust for double counting mortality .  \n17 Table 1. Natural history model parameters  \nTransition     \nFrom  To Age (years)  Annual \nprobability  Reference  \nStart prevalence HPV  ------  15 0.1 (18) \nStart prevalence CIN1  ------  15 0.01  (18) \nNo Lesion, HPV -negative  No Lesion, HPV -positive  15 - 19 0.1000 - 0.1700  (15-17, 28)   \na   20 - 23 0.1000 - 0.2025  \n  24 - 29 0.0550  \n  30 - 49 0.0120 - 0.0140  \n  50 and older  0.0045 - 0.0050  \nNo Lesion, HPV -positive  CIN1 (90 %)   0.1075  (15, 17, 18, 20, 28)   \na  \nNo Lesion, HPV -positive  CIN2 (10 %)   0.1075  (15, 17, 18, 20, 28)  \n \nCIN1  CIN2  15 - 34 0.0176  (16, 18, 21, 23, 24, \n28) a \n  35 and older  0.0718   \nCIN2  CIN3  16 - 34 0.0389  (14) \n  35 - 44 0.0797   \n  45 and older  0.1062   \nCIN3 or CIS  Cancer FIGO I  15 - 24 0.0011  (29) \n  25 - 34 0.0013  a  \n  35 - 38 0.0300   \n  39 - 49 0.0650   \n  50 - 64 0.0820  \n  65 and older  0.0831   \nCancer FIGO I  Cancer FIGO II   0.2933  (13) a \n \nCancer FIGO II  Cancer FIGO III   0.2793  (13) \n \nCancer FIGO III  Cancer FIGO IV   0.3461  (13) a \n \n    (16, 18, 21, 23, 24, \n28) a No Lesion, HPV -positive  No Lesion, HPV -negative  15 - 24  0.8026  \n  25 - 29 0.4621   \n  30 and older  0.1083   \nCIN1  No Lesion, HPV -negative \n(90 %)  15 - 34 0.1750  (16, 18, 21, 23, 24 , \n28) \n  35 and older  0.0851  \nCIN1  No Lesion, HPV -positive \n(10 %)  15 - 34 0.1750  (16, 18, 21, 23, 24, \n28) \n  35 and older  0.0851  \nCIN2  No Lesion, HPV -negative \n(50 %)   0.0693  (16, 18, 21, 23, 24, \n28) \nCIN2  CIN1 (50 %)   0.0693  (16, 18, 21, 23, 24, \n28) \nCIN3  No Lesion, HPV -negative \n(50 %)   0.0693  (16, 18, 21, 23, 24, \n28) \nCIN3  CIN2 (50 %)   0.0693  (16, 18, 21, 23, 24, \n28) \nNon-symptomatic  symptomatic     \nCancer FIGO I  Cancer FIGO I   0.150  (13) \nCancer FIGO II  Cancer FIGO II   0.225  (13) \nCancer FIGO III  Cancer FIGO III   0.600 (13) \nCancer FIGO IV  Cancer FIGO IV   0.900  (13) \nCIN: cervical intraepithelial neoplasia, CIS: carcinoma in situ, FIGO: invasive cancer stage classification F\u00e9d\u00e9ration \nInternationale de Gyn\u00e9cologie et d'Obst\u00e9trique, HPV:  human papillomavirus.  \na calibrated model parameter.   \n18  \n4.4.2 Population C haracteristics  \nThe model follows a cohort of 15 year old women not vaccinated against high -risk human \npapilloma virus 16 and 18. For the starting cohort, HPV prevalence was  assumed to be  10% , \nand CIN 1 prevalence 1%  (18).  \n4.4.3 Screening A dherence  \nWe used aggregated data reported for screening adherence in Germany. In the absence of \nindividual data, screening adherence was modeled to be independent from sc reening \nhistory. Using published German data on age -specific screening adherence (overall mean in \nthe base -case  analysis : on average 70 -80% for the age younger than 55  yrs), the same \nscreening adherence rates were applied  simultaneously to all screening st rategies including \nall screening intervals ( Table 2) (30). Due to lack of individual screening pattern data, no \nsystematic screening adherence patterns could have been considered. Compliance with \nfollow -up of abnormal screening results, diagnosis and treatment was considered to be \n100%.  \nTable 2. Age-specific screening adherence  \nAge (years)  Screening adherence  Source  \n20 - 29 0.79 -0.81  \nKerek -Bodden 2008 (31)  30 - 39 0.80 -0.78  \n40 - 49 0.74 -0.72  \n50 - 59 0.69 -0.66  \n60 - 69 0.62 -0.55  \n70 - 79 0.43 -0.32  \n80 +  0.17  \n \n4.4.4 Screening T est Characteristics  \nPrimary screening test sensitivity and specificity data for cytology alone, HPV alone and co -\ntesting with HPV plus cytology were derived from international meta -analyses (31-34) and  \n19 are displayed in Table 3. The meta -analysis of Arbyn et al. (31)  reported similar test \nperformance data for HPV tests other than hybrid capture 2 ( HC2). Therefore, in our model \nall HPV screening strategies include an HPV test with high performance and we used the test \nperformance data for HC2 as a proxy for all HPV tests.  As there is no scientific evidence for \nhigher sensitivity or specificity with liquid -based cytology screening, we assumed the same \ntest characteristics  in all strategies using LBC as a screening test.  \nTest accuracy data for secondary testing (e.g. , triage after positive primary HPV test) were \nderived from the published international literat ure (35-37) (Table 4). For the triage with \ncytology or LBC , we assumed the same sensitivity and specificity data as used in primary \ntesting. For colposcopy/biopsy, we used 96% sensitivity and 48% specificity (38). For \nsimplicity, the model assumes that a positive biopsy will always diagnose the true underlying \nhealth state and that a colposcopy -directed biopsy will always diagnose  the true underlying \nhealth state.  \nTable 3. Model parameters : screening  test characteristics  \nScreening \ntest Threshold  Sensitivity \n(%) 95% CI  \n(range)  Specificity \n(%) 95% CI  Reference  \nCytology  (ASCUS+) / CIN1 +  47.1  44.8 -49.4  94.2  93.3-95.2  Arbyn et al. 2012, \nCuzick et al. 2006, \nNanda et al. 2000 \n(31, 32, 34)   (ASCUS+) / CIN2 +  70.3*  62.5 -78.9*    \n (ASCUS+) / CIN3 +  68.5* 55.4 -85.2*    \nHPV  (1 pg/ml) / CIN1 +  80.6  76.3 -84.3  91.4  89.8 -92.9  Arbyn et al. 2012, Cuzick et al. 2006 \n(31, 32)   (1 pg/ml) / CIN2 +  96.3  94.5 -98.1    \n (1 pg/ml) / CIN3 +  98.0  97.0 -99.0    \nHPV + \nCytology   (1 pg/ml / ASCUS+) / \nCIN1 +  81.5  76.8 -84.8  88.8  85.5 -92.1  \nArbyn et al. 2 012, \nCuzick et al. 2006 (31, 32)   (1 pg/ml / ASCUS+) / \nCIN2 +  99.8  99.0 -100.0    \n (1 pg/ml / ASCUS+) / \nCIN3 +  99.8  99.0 -100.0    \nASC-US: Atypical squamous cells of undetermined significance, CIN: cervical intra epithelial neoplasia, HCII: Hybrid \nCapture II, HPV: Human papillomavirus, CI: confidence interval, LSIL: low -grade squamous intraepithelial lesion, \nPap: Papanicolaou test. *calculated based on relative sensitivity HC2 vs. cytology (basecase: 1.37 for (ASCU S+)/ \nCIN2+ and 1.43 for (ASCUS+)/ CIN3+) in European and North- American studies  \n  \n20 Table 4. Test accuracy data of secondary tests (triage)  \nScreening \ntest Threshold  Sensitivity \n(%) 95% CI  \n(range)  Specificity \n(%) 95% CI  Reference  \n Triage of Pap ASCUS      \nHPV  (1 pg/ml) / CIN1 +  90.9\u00a7  82.2 -96.3  36.3  30.7 -42.2  Schmidt et \nal. 2011 (36)   (1 pg/ml)  / CIN2 +  90.9  82.2 -96.3    \n (1 pg/ml) / CIN3 +  90.2  78.6 -96.7    \nP16/Ki -67 (\u2265 1 cell) /CIN1+  92.2\u00a7  83.8- 97.1\u00a7  80.6 75.6- 85.1 Schmidt et \nal. 2011 (36)   (\u2265 1 cell) /CIN2+  92.2 83.8- 97.1   \n (\u2265 1 cell) /CIN3+  92.2 81.1- 97.8   \n Triage of Pap LSIL       \nHPV  (1 pg/ml) / CIN1 +  96.4\u00a7  91.7- 98.8 19.1 14.6- 24.2 Schmidt et al. 2011 (36)  \n (1 pg/ml) / CIN2 +  96.4 91.7- 98.8   \n (1 pg/ml) / CIN3 +  95.8 88.3- 99.1   \nP16/Ki -67 (\u2265 1 cell) /CIN1+  94.2\u00a7  88.8 -97.4\u00a7  68.0  62.2 -73.4  Schmidt et \nal. 2011 (36)   (\u2265 1 cell) /CIN2+  94.2  88.8 -97.4    \n (\u2265 1 cell) /CIN3+  95.8  88.3 -99.1    \n Triage of HPV -positive       \nCytology  (ASCUS+) / CIN1 +  47.1  44.8 -49.4  94.2  93.3 -95.2  Arbyn et al. 2012, Cuzick \net al. 2006, \nNanda et al. \n2000 (31, \n32, 34)   (ASCUS+) / CIN 2 + 70.3*  62.5- 78.9*    \n (ASCUS+) / CIN3 +  68.5* 55.4- 85.2*    \nP16/Ki -67 (\u2265 1 cell) /CIN1+  91.9\u00a7  78.1- 98.3\u00a7  82.1 72.9- 89.2 Petry et al. \n2011 (35)  (\u2265 1 cell) /CIN2+  91.9 78.1- 98.3   \n (\u2265 1 cell) /CIN3+  96.4 81.7- 99.9   \n\u00a7 not reported in the literature, and therefore assumed to be the same as for CIN2+  \n \nIn the base -case analysis, we used conservative model parameters and model assumptions, \nthat is, in favor of cytology tests and against HPV tests.  Therefore, it is expected that in \nreality the benefit- harm balance and the cost effectiveness for the HPV -based screening \nstrategies is better than reported in our results when compared with the cytology -based \nscreening strategies. W e performed comprehensive sensitivity analyses and varied the \nmod el parameters for test sensitivity and specificity in order to assess robustness of results \nand identify need for further research . \n4.4.5 Resource Utilization and Cost Data \nAll health state costs were derived from the previously validated and published cost -\neffectiveness model for the German health care context and inflated to the index year 2014  \n21 by using the German  Consumer Price Index (CPI)  (www.destatis.de) . For screening tests , \ncurrent prices were applied.  \nDirect annual costs were calculated based on actual reimbursement costs, including \nfrequencies of diagnostic and laboratory testing, medication, and treatment procedures \nrelated to the specific cervical cance r stages. Health resource utiliz ation frequencies were \nderived from diagnostic and treatment guidelin es, HTA experts (10, 11, 26)  and experts from \nthe current guideline group. Reimbursement costs were derived from healthcare databases \nand applicable pharmaceutical prices. We adjusted reimbursement prices for ambulatory \ncare costs using a weighted average for East and West Germany and social and private \nhealth insurance from published data (39, 40) . Inpatient costs for cervical cancer treatment \nprocedures were based on Diagnosis Related  Groups (DRG).  \nTable  5 shows the direct medical costs for cervical cancer screening, diagnostic work -up, and \ntherapy, medications, follow -up and palliative procedures.   \n22 Table  5. Aggregated costs (per unit)  for screening, diagnostic work -up, therapy, and follow -\nup procedures  (Index year 201 4). \nProcedure  Costs (Euro)  \nScreening office visit 59 years a 32.82  \nScreening office visit until 60+ years a  33.82  \nControl office visit (cytology) 59 years a 16.58  \nContr ol office visit  (cytology) until 60+ years a 17.58  \nControl office visit (HPV or p16/Ki -67) 59 years a 23.17  \nControl office visit  (HPV or p16/Ki -67) until 60+ years a 24.17  \nPap cytology  7.40  \nLBC cytology  25.00  \nP16/Ki -67 dual stain  59.70  \nHPV test\u2021 30.40 \nColposcopy  23.98  \nBiopsy  21.12  \nConi zation until 39 years  462.10  \nConi zation 40 to 59 years  469.88  \nConi zation 60+ years  472.91  \nFollow -up after coniz ation until 59 years a  158.97  \nFollow -up after coniz ation 60+ years a  114.68  \nTherapy FIGO IA1 unti l 39 years  3,265.57  \nTherapy FIGO IA1 40 to 59 years  3,269.59  \nTherapy FIGO IA1 60+ years  3,271.16  \nTherapy FIGO IA2 until 39 years  4,518.36  \nTherapy FIGO IA2 40 to 59 years  4,520.96  \nTherapy FIGO IA2 60+ years  4,521.98  \nTherapy FIGO IB1 until 18 years  4,588.19  \nTherapy FIGO IB1 19 to 39 years  4,092.81  \nTherapy FIGO IB1 40 to 59 years  4,083.19  \nTherapy FIGO IB1 60+ years  4,085.36  \nTherapy FIGO IB2 until 18 years  5,707.10  \nTherapy FIGO IB2 19+ years  5,095.76  \nTherapy FIGO IIA until 18 years  6,081.91  \nTherapy  FIGO IIA 19+ years  5,412.10  \nTherapy FIGO IIB until 18 years  5,494.12  \nTherapy FIGO IIB 19+ years  4,295.39  \nTherapy FIGO III until 18 years  6,512.94  \nTherapy FIGO III 19+ years  4,862.68  \nTherapy FIGO IV until 18 years  7,346.86  \nTherapy FIGO IV 19+ years  5,573.06  \nFollow -up after cancer therapy until 59 years, year 1 and 2 after therapy a  635.88  \nFollow -up after cancer therapy 60+ years, year 1 and 2 after therapy a  639.88  \nFollow -up after cancer therapy until 59 years, year 3, 4 and 5 after therapy a  317.95  \nFollow -up after cancer therapy 60+ years, year 3, 4 and 5 after therapy a  319.94  \nFollow -up after cancer therapy until 59 years, year 6 after therapy a  158.97  \nFollow -up after cancer therapy 60+ years, year 6 after therapy a  159.97  \nPalliative cos ts until 18 years  6,007.00  \nPalliative costs 19+ years  6,794.82  \nFIGO: cervical cancer stage classification F\u00e9d\u00e9ration Internationale de Gy n\u00e9cologie et d'Obst\u00e9trique, HPV : Human \npapillomavirus, Pap: Pap cytology test. Screening costs: including reimburseme nt for gynecological work -up and \nlaborat ory costs for cytology. Control costs: reimbursement for follow -up testing and work -up is considered.  \na Aggregated costs per year .   \n23  \n4.5 Model Application and Analyses  \nThe decision -analytic model was calibrated, validate d and applied to perform benefit -harm \nanalyses and cost -effectiveness analyses. Analyses are based on deterministic cohort \nsimulations  using m ean values for all model parameters in the base -case analysis.  \nAll decision analyses were performed using the deci sion-analytic software package TreeAge \nPro 2014  (TreeAge Software Inc., Williamstown, MA, USA). All further statistical analyses \nwere performed with SAS 9 (SAS Institute Inc., Cary, North Carolina) and Excel (Microsoft). \nFor epidemiological calculations of aggregated measures, the Software EpiCalc 2000 Version \n1.02 ref (41) was applied.  \n4.5.1 Calibration  \nAs described previously (10, 11, 26) , the model was calibrated in a systematic and \nhierarchical manner  to fit specific epidemiologic data observed in an unscreened population \nin Germany . Epidemiologic data from the German Common Cancer Registry (CCR) from the \nyears 1964 -1966 were used to calibrate the model to fit cervical cancer incidence and FIGO -\nstage distribution. Age -specific HPV -incidence was calibrated such that the model predicted \nage-specific HPV prevalence as observed in a German population (42). For more information \non calibration methods and calibration results see prior publicat ions (10, 11, 26) . \n4.5.2 Validation  \nThe model was validated internally and externally on several levels  (43). First, plausibility \nand face validity checks  have been performed. Second, a technical verification  / debugging \nof the model programming code  has been cond ucted. Third, using cross -model validation, \nthe model structure and results have been compared with other published models. Forth, an internal validation for multiple criteria has been performed using independent \nepidemiological data from German cancer reg istries that have not been used to inform the \nmodel. Fifth, an external validation has been conducted comparing the model predictions with (a) epidemiological data from German cancer registries that have not been used to inform the model and its parameters  and with (b) German published literature data. The  \n24 following target parameters have been used for the validation: (1) age peak (in years) for the \ndevelopment of cervical carcinoma and cervical intraepithelial neoplasia (CIN 1 to CIN 3/CIS), \n(2) der incide nce peak  (per 100,000 women ), (3) the total incidence (per 100,000 women ), \n(4) the distribution of FIGO cancer stages I to IV (in percent), (5) the lifetime risk for a benign \nhysterectomy (in percent), (6) the lifetime risk for cervical cancer (in percent) , and (7) the \nlifetime risk for death due to cervical cancer (in percent).  The validation showed that m odel \npredictions for an unscreened population were consistent with independent data observed \nin Germany before introduction of screening.  \n \n4.5.3 Benefit -Harm A nalysi s \nWe used a benefit- harm frontier approach to analyze and visualize the trade -off between \nbenefits and harms. The incremental harm -benefit ratios are calculated for the lif elong time \nhorizon. The IHBR is defined by the difference in harms  (in harm un its), divided by the \ndifference in benefits (in benefit units) between two interventions:  \nIHBR = (H A-HB) / (B A-BB), \nwith H A and H B equal ing the total lifetime harms for intervention A and B, and BA and \nBB equal ing the total lifetime benefits for interventi on A and B.  \nThe incremental harm -benefit concept  and the IHBR  is illustrated in Figure 3. We visualize \nthe incremental harm -benefit ratio using the benefit -harm  frontier, where non -dominated \nstrategies lie on the benefit -harm fron tier line.  All strategies lying below this line are  more \nharm ful and equally or  less effective compared to other strategies  or combinations of other \nstrategies , and are therefore dominated by the strategies on the benefit- harm frontier. From \nthis graph  (Figure 3), we can directly derive the incremental harm -benefit ratio representing \nthe units  of harms we have to accept for one additional unit of benefit gained, if we consider \na specific intervention compared to the next  non-domina ted intervention.   \n25 Figure 3. Illustration of the benefit -harm frontier  concept  \n \nThe black line represents the benefit -harm frontier. All strategies lying below this line are  more harmful and \nprovide equal or  less benefit com pared t o other strategies or combinations of other strategies , and are therefore \ndominated by the strategies on the benefit -harm frontier. From this graph , we can directly derive the \nincremental harm -benefit ratio representing the additional units  of harms we have to accept for one additional \nunit of benefit gained, if we consider a specific intervention compared to the next  non- dominated intervention.  \n \n4.5.4 Cost -Effectiveness Analysis  \nThe discounted  ICER s are calculated for the lifelong time horizon. The discounted  ICER is \ndefined by the difference in  discounted  costs, divided by the difference in discounted  effects \nbetween two interventions  (Figure 4): \nICER = (C A-CB) / (E A-EB) \nWith C A and C B equal ing the total lifetime costs for intervention A and B , and  EA and E B \nequal ing the total lifetime effects for intervention A and B. We visualize the incremental \ncost-effectiveness ratio using the cost- effectiveness frontier, where non -dominated \nstrategies lie on the cost- effectiveness frontier line. All strategies lying below this line are \nmore costly and equally or less effective compared to other strategies  or combinations of \nother strategies , and are therefore dominated  by these strategies . From the incremental \n \n26 cost-effectiveness frontier , we can directly derive the ICER  representing the additional costs \n(in Euro)  we have to accept for one additional unit of benefit gained, if we consider a specific \nstrategy  compared to the next non-dominated strategy . \nFigure 4. Cost -Effective ness Frontier  \n \nThe black line represents the cost -effectiveness frontier. All strategies lying below this line are  more costly and \nequally or  less effective compared to other strategies  or combinations of other strategies , and are therefore \ndominated by t he strategies on the cost -effectiveness frontier. From this graph , we can directly derive the \nincremental cost-effectiveness ratio representing the additional costs  we have to accept for one additional unit \nof effectiveness (e.g., life years)  gained, if we consider a specific intervention compared to the next  non-\ndominated intervention.  \n \n4.5.5 Sensitivity Analyses  \nWe performed one- way and multi -way sensitivity analyses to evaluate the robustness of the \nresults. In the sensitivity analys es, we used lower and upper  95% CI limits or ranges derived \nfrom the published literature  to vary model parameters . In multi -way sensitivity analyses , \nPap cytology sensitivity values were varied using the lower 95% CI  limits for primary and \nsecondary (triage) test values , and for th e accuracy of colposcopy a specificity of 0.566  and a \nsensitivity of 0.760 for CIN1/CIN2 and 0.983 for  CIN3+ was used as reported in Cantor et al. \n \n27 2008 (44). Variation of test performances was particularly importan t as the assumption of \nindependence of test performance conditional on disease status for repeated tests may be \noverestimated for lesions with specific morphologic conditions. The s creening adherence \nwas increased to  100%  in the sensitivity analysis to pro vide results for \u201cintended strategies\u201d . \nIn the sensitivity analyses, t he cancer treatment costs were increased to 4 -fold of the base -\ncase values.  \n \n5 Results  \n5.1 Screening -Related Benefits  \n5.1.1 Reduction in Cervical Cancer Incidence  \nCompared to no screening with a ce rvical cancer incidence of 46.2 per 100,000 women, \nscreening with cytology or HPV -based strategies achieves a relative reduction in cervical \ncancer incidences by 72 \u2013  97% depending on screening interval and screening algorithm. \nWithin the same screening in terval,  HPV -based screening strategies are more effective ( with \nrelative reduction of 83.5% -96.2% for screening intervals 5 , 3 or  2 year s) compared with \ncytology screening strategies  (relative reduction of 7 2.4%-91.3% for 5, 3, 2, and 97.3 % for 1 \nyear) .  \nSwitching from 5 -yearly cytology screening to 5 -yearly HPV -based screening achieves further \n11% relative reduction in cervical cancer incidence . Switching from biennial cytology \nscreening to biennial HPV -based screening achieves further 3% relative reductio n in cervical \ncancer incidence.  Annual HPV -based screening was not considered in our analyses. \nComparing HPV -based screening strategies, all strategies were very similar regarding \neffectiveness.  \n  \n28 Table 6. Reduction in cervical cance r incidence  \n  Annual \ncancer \nincidence  Reduction in cancer \nincidence vs. no screening  \n  Absolute \nreduction  Relative \nreduction  \nStrategy  per \n100,000 \nwomen  per 100,000 \nwomen  % \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Interva ll 1J 1.27  44.97  97.3  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  1.27  44.97  97.3  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  1.27  44.96  97.3  \n3. Conv. Pap /  p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  1.27  44.96  97.3  \n2. Conv. Pap: Alter 20J, Intervall 1J  1.61  44.62  96.5  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  1.75  44.49  96.2  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  1.75  44.49  96.2  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  1.79  44.44  96.1  \n28. HPV / LBC Triage: Al ter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  1.84  44.39  96.0  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  1.84  44.39  96.0  \n23. HPV + LBC Cotesting: Alter >30J, I ntervall 3J; Pap: Alter 25J -30J, Intervall 2J  3.41  42.82  92.6  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  3.41  42.82  92.6  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J b is 30J, Intervall 2J  3.51  42.72  92.4  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  3.60  42.64  92.2  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Interv all 2J  3.60  42.64  92.2  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  4.04  42.20  91.3  \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  4.04  42.20  91.3  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  4.04  42.19  91.3  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  4.04  42.19  91.3  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alte r 25J -30J; Alter > 30J, Intervall 3J  7.11  39.12  84.6  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  7.11  39.12  84.6  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  7.12  39.11  84.6  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  7.12  39.11  84.6  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  7.31  38.92  84.2  \n21. HPV + Conv. Pap Cot esting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  7.31  38.92  84.2  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  7.50  38.73  83.8  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  7.63  38.61  83.5  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  7.63  38.61  83.5  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; A lter > 30J, Intervall 5J  12.75  33.49  72.4  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  12.75  33.49  72.4  \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  12.75  33.48 72.4  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  12.75  33.48  72.4  \n1. Kein Screening  46.23  0.00  0.0 \n \n5.1.2 Reduction in Cervical Cancer Mortality  \nCompared to no screening with a cervical cancer mortality  of 17.6 per 100,000 women, \nscreening with cytology or HPV -based st rategies achieves a relative reduction in cervical \ncancer mortality  by 79  \u2013 99% depending on screening interval and screening algorithm. \nWithin the same screening interval , HPV -based screen ing strategies are more effective (with  \n29 relative reduction of 8 8.7%-98.1% for screening intervals 5, 3 or 2 years) compared with \ncytology screening strategies ( relative reduction of 78 .5%-94.8% for 5, 3, 2, and  98.7 % for 1 \nyear).  \nSwitching from 5 -yearly c ytology screening to 5 -yearly HPV -based screening achieves further \n11% relative reduction in cervical cancer mortality . Switching from biennial cytology \nscreening to biennial HPV -based screening achieves further relative 3% reduction in cervical \ncancer mortality .  \n30 Table 7. Reduction in cervical cancer mortality  \n Annual \nmortality from \ncancer  Reduction in mortality \nfrom cancer vs. no \nscreening  \n  Absolute \nreduction  Relative \nreduction  \nStrategy  per 100,000 \nwomen  per 100,000 \nwomen  % \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  0.23  17.32  98.7  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  0.23  17.32  98.7  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Interval l 2J Alter 25J -30J; Alter > 30J, Intervall 1J  0.23  17.32  98.7  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  0.23  17.32  98.7  \n2. Conv. Pap: Alter 20J, Intervall 1J  0.29  17.26  98.3  \n22. HPV + LBC Cotesting : Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  0.33  17.22  98.1  \n19. HPV + Conv. 17,32/  Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  0.33  17.22  98.1  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  0.34  17.21  98.0  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  0.35  17.19  98.0  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alte r 25J bis 30J, Intervall 2J  0.35  17.19  98.0  \n23. HPV + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  0.74  16.80  95.8  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  0.74  16.80  95.8  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  0.77  16.78  95.6  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  0.79  16.76  95.5  \n26. HPV / Conv. P ap-Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  0.79  16.76  95.5  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  0.92  16.63  94.8  \n8. Conv. Pap / HPV Triage: Alter 25J, Interva ll 2J Alter 25J -30J; Alter > 30J, Intervall 2J  0.92  16.63  94.8  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  0.92  16.63  94.8  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30 J, Intervall 2J  0.92  16.63  94.8  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  1.85  15.70  89.5  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  1.85  15.70  89.5  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  1.85  15.70  89.5  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  1.85  15.70  89.5  \n24. HPV + LBC Cotesting: Alter >30J, Inte rvall 5J; Pap: Alter 25J -30J, Intervall 2J  1.88  15.66  89.3  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  1.88  15.66  89.3  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  1.95  15.60  88.9  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  1.98  15.57  88.7  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall  2J 1.98  15.57  88.7  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  3.78  13.77  78.5  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  3.78  13.77  78.5  \n14. LBC / p16/Ki -67 T riage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  3.78  13.77  78.5  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  3.78  13.77  78.5  \n1. Kein Screening  17.55  0.00  0.0 \n \n5.1.3 Gains in Remainin g Life Expectancy  \nCompared to no screening with a remaining life expectancy of 67.9 years (for a 15 -year old \nwoman) , screening with cytology or HPV -based strategies achieves on average 0.21 -0.26 life-\nyears gained (75.1 -  93.4 life days  gaine d), depending o n screening interval  and screening \nalgorithm .  \n31 Within the same screening interval , HPV -based screening strategies are more effective , \nyielding an expected gain in life years compared to no screening of 0.23 to 0.2 6 life-year \ngained for 5 - to 2-yearly screen ing), compared with cytology screening strategies yielding an  \nexpected  gain in life years c ompared to no screening of 0.2 1 to 0.2 5 life-year gained for 5 - to \n2-yearly screening .  \nSwitching from 5 -yearly cytology screening to 5 -yearly HPV -based screening ac hieves on \naverage 0.027 life-year gained (i.e., 9.7 life-days gained). Switching from biennial cytology \nscreening to biennial HPV -based screening achieves on average 0.008 life year gained (i.e., \n3.1 life-days gained).   \n32 Table 8. Rema ining life expectancy  \n Life years  Life-years gained vs. \nno screening  \n1. Kein Screening  67.90656  \n 6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  68.11225  0.205692  \n14. LBC / p16/Ki -67 Triage: Alter 25J, I ntervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  68.11225  0.205692  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  68.11229  0.205732  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J , Intervall 5J  68.11229  0.205732  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.13879  0.232237  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Interval l 2J 68.13879  0.232237  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.13927  0.232713  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  68.13959  0.233033  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  68.13959  0.233033  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  68.13962  0.23306  \n17. LBC / HPV Triage: A lter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  68.13962  0.23306  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  68.14024  0.233686  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  68.14024  0.233686  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  68.15295  0.246391  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  68.15295  0.246391  \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  68.15296  0.246408  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  68.15296  0.246408  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.15525  0.248694  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.15525  0.248694  \n32. HPV / p16/Ki -67 Triage: Alter >30J , Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.15551  0.248953  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  68.15595  0.24939  \n23. HPV + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alte r 25J -30J, Intervall 2J  68.15595  0.24939  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.16115  0.254593  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.16115  0.254593  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  68.16129  0.254733  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  68.16145  0.254891  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  68.16145  0.254891  \n2. Conv. Pap: Alter 20J, Intervall 1J  68.16189  0.255334  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  68.1625  0.255944  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  68.1625  0.255944  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  68.1625  0.255949  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  68.1625  0.255949  \n \n5.2 Screening -Related Harms  \n5.2.1 Total Number of Positive Screening Test Results  \nDepending on scree ning strategy and interval test , the total number of positive screening \nresults varies  by a factor of 4 . Cytology -based screening results in 70 (5-year interval) to 281 \n(annual screening) screen -positive test results per 100 screened women. HPV -based  \n33 screening results in 92 (5 -year interval) to 206 (2 -year interval)  screen -positive test results \nper 100 screened women.  \nWithin the same screening interval , HPV -based screening results in more positive screening \ntests compared to cytology.  Cotesting with HPV and cytology results in  a relative increase of \n12-15% (depending o n screening interval) in positive test results.  \nTable 9. Total number of positive screening test results  \nStrategy  Total number of positive \nscreening test results  \nper 100 screened women  \n1. Kein Screening  0.00  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  69.78  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  69.78  \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Inte rvall 5J  69.79  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  69.79  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  91.48  \n30. HPV / LBC Triage:  Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  91.54  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  91.54  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  96.69  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  96.69  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  96.70  \n5. Conv. Pap / p16 /Ki-67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  96.70  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  102.73  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  102.73  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  128.63  \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  128.63  \n12. LBC / p16/Ki -67 Triage: Alter 25J, I ntervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  128.65  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  128.65  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  131.06  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  131.18  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  131.18  \n23. HP V + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  149.61  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  149.61  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pa p: Alter 25J bis 30J, Intervall 2J  178.46  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  178.67  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J 178.67  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  205.95  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  205.95  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  222.66  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  222.66  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  222.68  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  222.68  \n2. Conv. Pap: Alter 20J, Intervall 1J  281.03  \n  \n34 5.2.2 Total Number of C olposcopies  \nDepending on screening strategy and interval , the total number of colposcopies varies by a \nfactor of 4 . Cytology -based screening results in 52 (5 -year interval) to 224 (annual screening) \ncolposcopies per 100 screened women compared to 60 (5 -year interval) to 121 (2 -year \ninterval) colposcopies per 100 screened women with HPV -based screening.  \nWithin the same screening interval, HPV -based screening results in more colposcopies \ncompared to cytology. With screening in 5 year intervals, cotesting with HPV plus  cytology \nresults in 15% (relative) more colposcopies and HPV screening with a triage in 16 % (relative) \nmore colposcopies compared to cytology screening. With a  2-year screening interval, \ncytology with dual stain triage results in 44% (relative) less colposcopies than cytology with \nHPV triage. Compared to biennial cytology with dual stain triage , screening with HPV -based \nstrategies results in 6%  (cotesting HPV + cytology) to 34% (HPV + dual stain triage) more \ncolposcopies , but colposcopy rates of HPV -based screening strategies are lower than for \nbiennial cytology with HPV triage.   \n35 Table 10. Total number of colposcopies  \nStrategy  Total number of colposcopies  \nper 100 screened women  \n1. Kein Screening  0.00  \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  52.44  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  52.44  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  60.21  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Interv all 2J  60.21  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  60.79  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  60.79  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  70.36  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  70.36  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; P ap: Alter 25J bis 30J, Intervall 2J  70.47  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  72.58  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  72.58  \n23. HPV + LBC Cotes ting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  77.30  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  77.30  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J,  Intervall 2J  78.30  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  78.30  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  90.97  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  90.97  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  94.12  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Al ter 25J -30J, Intervall 2J  96.82  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  96.82  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  98.32  \n25. HPV / Conv. Pa p-Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  98.32  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  99.59  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  99.59  \n2. Conv. Pap: Alter 20J, Intervall 1J  106.00  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  121.63  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; A lter > 30J, Intervall 2J  131.33  \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  131.33  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  150.39  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  150.39  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  224.09  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J , Intervall 1J  224.09  \n \n5.2.3 Total Number of C onizations  \nDepending on screening strategy and interval , the total number of conizations varies  by a \nfactor of 1.5.  Cytology -based screening results in 7.3 (5 -year interval) to 11.1 (annual \nscreening) conizations pe r 100 screened women compared to 8.5 (5 -year interval) to 10.5 (2 \nyear interval) conizations per 100 screened women with HPV -based screening.  The total \nnumber of conizations below CIN3 is similar in all cytology strategies (with HPV or dual stain \ntriage) w ithin the same screening interval.   \n36 Within the same screening interval, HPV -based screening results in more conizations  \ncompared to cytology. With screening in 5 year intervals, cotesting with HPV plus cytology \nresults in 17% (relative) more conizations an d HPV screening with a triage in 16% (relative) \nmore conizations  compared to cytology screening.  Compared to bienn ial cytology, screening \nwith bienn ial HPV -based strategies results in 8% (HPV + cytology  triage ) to 9 % (HPV + dual \nstain triage  or cotesting H PV + cytology ) more total numbers of conizations per 100 screened \nwomen.  \nTable 11. Total number of conizations  \nStrategy  Total number of conizations  \nper 100 screened women  \n1. Kein Screening  0 \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  7.332211  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  7.332211  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J 7.336495  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  7.336495  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  8.508229  \n27. HPV / Conv. Pap -Triage: A lter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  8.508229  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  8.556666  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  8.586437  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  8.586437  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  8.706213  \n5. Conv. P ap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  8.706213  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  8.710712  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  8.710712  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  9.616706  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  9.616706  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  9.621273  \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  9.621273  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J  ; Pap: Alter 25J bis 30J, Intervall 2J  9.700893  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  9.700893  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  9.750206  \n23. HPV + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  9.757853  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  9.757853  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  10.42027  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  10.42027  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J-30J, Intervall 2J  10.45538  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  10.45538  \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  10.47316  \n11. LBC  / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  10.74401  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  10.74401  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J-30J; Alter > 30J, Intervall 1J  10.74875  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  10.74875  \n2. Conv. Pap: Alter 20J, Intervall 1J  11.05292  \n  \n37 5.2.4 Total Number of C onizations < CIN3  \nDepending on screening st rategy and interval the total number of conizations below CIN3 \nvaries 1. 8\u2013fold. Cytology -based screening results in 5.4 (5 year interval) to 9.5 (annual \nscreening) conizations per 100 screened women compared to 6.4 (5 year interval) to 8.8 (2 \nyear interval ) conizations below CIN3 per 100 screened women with HPV -based screening. \nThe total number of conizations below CIN3 is similar in all cytology strategies (with HPV or \ndual stain triage) within the same screening interval.  \nWith screening in 5 year intervals, cotesting with HPV plus cytology or HPV with dual stain \ntriage results  in 21% (relative) and HPV screening with cytology  triage in 20% (relative) more \nconization below CIN3 compared to cytology screening. Compared to biennial  cytology, \nscreening with b ienn ial HPV -based strategies results in 13 % (HPV + cytology triage) , 14% \n(HPV + cytology cotesting), and 15 % (HPV + dual stain triage) more conizations below CIN3 \nper 100 screened women.   \n38 Table 12. Total number of conizations < CIN 3  \nStrategy  Total number of conizations < \nCIN 3  \nper 100 screened women  \n1. Kein Screening  0.00000  \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  5.36781  \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  5.36781  \n18. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  5.37349  \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  5.37349  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  6.41906  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  6.41906  \n33. HPV / p16/Ki -67 Triage: Alter >30J , Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  6.48938  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  6.49686  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Interval l 2J 6.49686  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  6.67483  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  6.67483  \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  6.68136  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  6.68136  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  7.70511  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  7.70511  \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  7.71222  \n8. Conv. Pap / HPV Triage: Alter 25J, Inter vall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  7.71222  \n29. HPV / LBC Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  7.76798  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis  30J, Intervall 2J  7.76798  \n23. HPV + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  7.83389  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  7.83389  \n32. HPV / p16/Ki -67 Triage: Alter >3 0J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  7.85103  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  8.74462  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1 J ; Pap: Alter 25J bis 30J, Intervall 2J  8.74462  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  8.78594  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  8.78594  \n31. HPV / p16/ Ki-67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, Intervall 2J  8.84313  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  9.22593  \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Interval l 2J Alter 25J -30J; Alter > 30J, Intervall 1J  9.22593  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  9.23405  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  9.23405  \n2. Conv. Pap: Alter 20J, Intervall 1J  9.47039  \n \n5.3 Benefit -Harm Balance  \n5.3.1 Benefit -Harm Analyse s Using Screening T est Positive Results  as Harm Outcome  \nFigure 5 shows the relation between total number of screen ing test -positive results  and t he \nreduction in cervical cancer cases per 100 screened women.  Strategies positioned below the \nbenefit -harm frontier are dominated, that is, compared to (combinations of) other  \n39 strategies, they yield less benefit (i.e., reduction of cervical cancer risk) wh ile generating \nmore harm (i.e., test- positive results).  \nFor example, in order to prevent  1 additional cervical cancer case in 100 screened women \nwith 5 -yearly cytology screening, there are 31 additional positive screening test results. The \ncorresponding nu mbers for the IHBR are 61 additional positive screening test results per \nprevented cervical cancer case for 5 -yearly HPV with dual triage . and 146 additional positive \nscreening test results  for 3 -yearly HPV with dual triage For shorter screening intervals,  the \nefficiency curve becomes less steep , for instance, showing more than 4 00 additional positive \nscreening test results  for 2 -yearl y HPV -based strategies.  \n5-yearly or 3-yearly HPV screening with dual triage  seems to result in a good balance \nbetween benefi ts (reduction in cancer) and harms associated with positive test results.  \nFigure 5. Benefit -harm frontier: Reduction in cervical cancer cases versus total number \nprimary screening test -positive results  \n \n \n40  \nFigure 6 shows the relation between total number of screen ing test -positive results  and the \nreduction in cervical cancer mortality  per 100 screened women. In order to save  1 woman \nfrom dying due to cervical cancer in 100 screened women , there are additional 75 positive \nscreening test results  with 5 -yearly cytology, 174 with  5-yearly HPV with  dual triage , 494 \nwith 3 -yearly HPV with  dual triage, 1,620  with  bienn ial HPV with dual stain triage, and 5,594 \nwith  annual  cytology. All other screening strategies are dominated.  \n5-yearly or 3-yearly HPV with  dual triage  seems to result in a good balance between benefits \n(reduction in cancer  death ) and harms associated with positive test results.  \nFigure 6. Benefit -harm frontier: Reduction in cerv ical cancer mortality versus total number \nprimary screening test -positive results  \n \n \n \n41 Figure 7 shows the relation between total number of screen ing test -positive results  and the \ngain in remaining life expectancy per screened wom an. In order to gain 1 life year due to \nscreening, there are on average 3 additional positive screening test results with 5 -yearly \ncytology, 8 with 5- yearly HPV with  dual triage , 24 with 3 -yearly HPV with  dual triage , 82 with \nbienn ial HPV with  dual triage , and 363 with annual  cytology during women \u2019s lifetime . All \nother screening strategies are dominated.  \n5-yearly or 3-yearly HPV with  dual triage  or triennial HPV with dual stain triage seem to \nresult in a good balance between benefits ( gain in life expectancy ) and harms associated \nwith positive test results.  \nFigure 7. Benefit -harm frontier: Life -years gained versus total number primary screening \ntest-positive results  \n \n \n \n42 5.3.2 Benefit -Harm Analys es Using Colposcopies  as Harm Outcome  \nFigure 8 shows the relation between total number of colposcopies and the reduction in \ncervical cancer cases per 100 screened women. In order to prevent 1 additional cervical \ncancer case , there are additional 23 colposcopies with 5 -yearly HPV plus cytology cotesting, \n64 colposcopies with 3 -yearly HPV plus cytology cotesting, 172 colposcopies with bienn ial \nHPV plus cytology cotesting, 972 colposcopies with current annual cytology, 1,919 colposcopies with annual cytology with  dual stain triage , and 469,783 colposcopies with \nannual cytology with  HPV triage . All other strategies are dominated.  \nHPV plus cytology cotesting every 5 or 3 years  (depending on the willingness to accept \ncolposcopies) seem to result in a good balance between benefits (reduction in cancer) and \nharms associated with numbers of colposcopies.  \nFigure 8. Benefit -harm frontier: Reduction in cervical cancer cases versus total number \ncolposcopies  \n \n \n43  \nFigure 9 shows the relation between total number of colposcopies and the reduction in \ncervical cancer death  per 100 screened women. In order to prevent 1 death from  cervical \ncancer , there are additional  56 colposcopies with 5 -yearly cytology with  dual stain triage, 60  \ncolposcopies with 5 -yearly HPV plus cytology cotesting, 220 colposcopies with 3 -yearly HPV \nplus cytology cotesting,  696 colposcopies with bienn ial HPV plus cytology cotesting, 3,233 \ncolposcopies with current annual cytology, 10,323 colposcopies with annual cytology with  \ndual stain triage , and 2,656,152  colposcopies with annual cytology with  HPV triage . All othe r \nstrategies are dominated.  \nHPV plus cytology cotesting every 5 or 3 years  (depending on the willingness to accept \ncolposcopies) seem to result in a good balance between benefits (reduction in cancer  death ) \nand harms associated with numbers of colposc opies .  \n44 Figure 9. Benefit -harm frontier: Reduction in cervical cancer mortality versus total number \ncolposcopies  \n \n \nFigure 10 shows the relation between total number of colposcopies and the gain in life \nexpectancy per screened woman. In order to gain 1 life year due to screening , there are \nadditional 3 colposcopies with 5 -yearly cytology with  dual stain triage, 3 colposcopies with 5 -\nyearly HPV plus cytology cotesting, 11 colposcopies with 3 -yearly HPV plus cytology \ncotesting, 35 colposcopies with bienn ial HPV plus cytology cotesting, 207 colposcopies with \ncurrent annual cytology, 728 colposcopies with annual cytology with  dual stain triage, and \n147,397 colposcopies with annual cytology and HPV triage over the lifetime of screened \nwomen . All other strategies are dominated.  \nHPV plus cytology cotesting every 5 or 3 years  (depending on the willingness to accept \ncolposcopies) seem to result in a good balance between benefits ( increase in life -years \ngained) and harms associated with numbers of colposcopies.  \n \n45 Figure 10. Benefit -harm frontier: Life -years gained versus total number colposcopies  \n \n \n5.3.3 Benefit -Harm Analyses Using Conization < CIN3  as Harm Outcome  \nFigure 11 shows the relation between total number of conizations below CIN3 and the \nreduction in cervical cancer cases per 100 screened women. In order to prevent 1 additional \ncervical cancer case , there are additional  2 conizations below CIN3 with 5 -yearly cytology \nwith triage, 3 conizations below CIN3 with 5 -yearly HPV with cytology triage, 4 conizations \nbelow CIN3 with 5 -yearly HPV plus cytology cotesting, 5 conizations below CIN3 with 3 -\nyearly HPV with cytology triage, 5 conizations below CIN3 with 3 -yearly HPV plus cytology \ncotesting, 8 conizations below CIN3 with 2 -yearly HPV plus cytology cotesting, 14 conizations \nbelow CIN3 with annual cytology with dual  triage , and 52  conizations below CIN3 with \nannual cytology with HPV  triage . All other strategies are dominated.  \n \n46 HPV plus cytology cotesting or HPV with cytology triage every 5 or 3 years seem to result in a \ngood balance between benefits (reduction in cancer) and harms associated with numbers of \nconizations below CIN3 . It should be mentioned that s everal other strategies are positioned \nclosely  to the latter.  \nFigure 11. Benefit -harm frontier: Reduction in cervical cancer cases versus total number \nconizations < CIN 3  \n \n \nFigure 12 shows the relation between total number of conizations below CIN3 and the \nreduction in cervical cancer mortality per 100 screened women. In order to prevent 1 \n \n47 additional cervical cancer death , there are additional 6 conizations below CIN3 with 5 -yearly \ncytology with triage, 9 conizations below CIN3 with 5 -yearly HPV with cytology triage, 1 7 \nconizations below CIN3 with 3 -yearly HPV plus cytology cotesting, 34 conizations below CIN3 \nwith bienn ial HPV plus cytology cotesting, 62 conizations below CIN3 wi th annual cytology \nwith dual  triage, and 2 93 conizations below CIN3 with annual cytology  with HPV triage . All \nother strategies are dominated.  \nHPV with a triage every 5  or 3  years seem s to result in a good balance between benefits \n(reduction in ca ncer  deaths ) and harms associated with numbers of conizations below CIN3.  \nFigure 12. Benefit -harm frontier: Reduction in cervical cancer mortality versus total \nnumber conizations < CIN 3  \n \n \n48  \nFigure 13 shows  the relation between total number of conizations below CIN3 and the gain \nin life expectancy per screened woman. In order to gain 1 life year due to screening , there \nare additional 0.3 conizations below CIN3 with 5 -yearly cytology with  triage, 0.4 conizations \nbelow CIN3 with 5 -yearly HPV with cytology triage, 0.5 conizations below CIN3 with 5 -yearly \ncotesting with HPV and cytology, 0.8 conizations below CIN3 with 3 -yearly HPV with cytology \ntriage, 0.9 conizations below CIN3 with 3 -yearly cotesting with HPV and cytology,  1.7 with 2-\nyearly cotesting with HPV and cytology, 4.2 with annual cytology with  dual triage , and 16.2 \nwith annual cytology with  HPV  triage   over the lifetime of screened women . All other \nstrategies are dominated.  \nHPV plus cytolog y cotesting or HPV with cytology triage every 5 or 3 years (depending on the \nwillingness to accept conizations) seem to result in a good balance between benefits \n(increase in life -years gained ) and harms associated with numbers of colposcopies.  \n  \n49 Figure 13. Benefit -harm frontier: Life -years gained versus total number conizations < CIN 3   \n \n5.4 Incremental Cost-Effectiveness  \nTable 13 shows the discounted total lifetime costs, discounted life expectancy, and the \ndisco unted ICER . \nFigure 14 shows the cost -effectiveness frontier with 5 -yearly screening with cytology and \nHPV triage or HPV screening and cytology triage, 3 -yearly HPV and cytology triage, bienn ial \nHPV and cytology triage, and annual cytology with HPV triage on the cost -effectiveness  \nfrontier line. All other strategies are dominated by absolute or extended dominance.  \n \n50 The corresponding ICERs  are 4,212 Euro/LYG for 5- yearly screening with cytology and HPV \ntriage, 9,210 Euro/LYG for 5 -yearly screening with HPV and  cytology triage, 30,599 Euro/LYG \nfor 3 -yearly HPV with cytology triage, 107,715 Euro/LYG for bienn ial HPV with cytology \ntriage, and 531,379 Euro/LYG for annual cytology with HPV triage.  \n5-yearly screening with HPV and cytology t riage  is superior to 5-yearly screening with \ncytology and HPV with cytology triage  and is very cost effective. 5 -yearly cotesting is only \nslightly more effective but more costly. 3-yearly HPV with cytology triage  is estimated to \nachieve even higher life ex pectancy  and still seems to be cost effective when compared with \nother well -accepted interventions in health and medicine  (45), that is, 3 -yearly HPV with \ncytology triage  seems to provide a good balance between benefits ( life-years gained ) and \ncosts.  \n  \n51 Table 13. Base -case results: discounted total costs, effects,  and incremental cost -\neffectiveness ratios  \n Total costs \n(Euro)  Total life \nexpectancy  \n(Life years)  ICER \n(Euro/LYG)  \n1. Kein Screening  91.4  28.92655  0 \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  253.2  28.964 97 4,212 \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  259.5  28.96496  Dom.  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  298.1  28.96985  9,210 \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  310.5  28.97012  Ext dom.  \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  312.3  28.96993  Dom.  \n33. HPV / p16/Ki -67 Triage : Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  315.6  28.96994  Dom.  \n5. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  320.4  28.96993  Dom.  \n18. LBC / HPV Triage: Alter 25J, In tervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  326 28.96497  Dom.  \n14. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  330.6  28.96496  Dom.  \n30. HPV / LBC Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Al ter 25J bis 30J, \nIntervall 2J  334.1  28.96985  Dom.  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  390.0  28.97285  30,599 \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 3 0J, Intervall 2J  390.1  28.9724  Dom.  \n24. HPV + LBC Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  393.5  28.97012  Dom.  \n4. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  400.2  28.9724  Dom. \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  408.6  28.96993  Dom.  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  410.3  28.97298  Ext. dom.  \n13. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  414.4  28.96993  Dom.  \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  417.5  28.9729  Dom.  \n29. HPV / LBC Triage: Alter >30J, Intervall   HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  427.5  28.97285  Dom.  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  506.9  28.97394  107,715 \n16. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  515.3  28.9724  Dom.  \n23. HPV + LBC Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  520.4  28.97298  Dom.  \n12. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J 522.4  28.9724  Dom.  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  536.6  28.97399  Ext. dom.  \n28. HPV / LBC Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  546.0  28.97394  Dom. \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis 30J, \nIntervall 2J  546.4  28.97396  Dom.  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  630.0  28.97417  531,379 \n3. Conv . Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  646.2  28.97417  Dom.  \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  680.0  28.97399  Dom.  \n2. Conv. Pap: Alter 20J, Intervall 1J  802.2  28.9741  Dom.  \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  841.4  28.97417  Dom.  \n11. LBC / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  852.4  28.97417  Dom.  \nICER: increment al cost -effectiveness ratio , LYG: life -years gained  \n  \n52 Figure 14. Base -case results: c ost-effectiveness frontier  \n \n \n \n53 6 Results: Sensitivity Analyses  \n6.1 Benefit -Harm Balance  \nIn general, the model results for the benefit- harm analyses were very robust when selected \nparameters were varied across plausible ranges in sensitivity analyses. Triennial HPV \nscreening with cytology triage or cotesting may be considered as having a good balance \nbetween benefits and potential harms even when the accura cy of cytology or colposcopy is \nreduced. In women attending the screening program regularly (100% adherence) , one may \nconsider extending the screening interval to 5 years in orde r to balance benefits and harms, \nif no other factors prohibit such a large screening interval.  \n6.1.1 Screening Test -Positive Results  \nSensitivity of Cytology  \nIn multi -way sensitivity analyses Pap cytology sensitivity values were varied using the lower \n[44.8% (CIN1), 62.5% (CIN2), 55.4% (CIN3+)] 95% CI limits. All strategies that have Pap \ncytology as a primary screening test or as a follow -up test are influenced simultaneously in \nthis analysis.  \nTable 14 shows the incremental harm -benefit ratios (in positive tests / LYG) for the non -\ndominated strategies, if the test sensitivity values for the Pap cytology test are varied \naccording to the lower 95% CIs.  \nFigure 15 shows the relation between total number of screen -positives and the gain in \nremaining life expectancy per screened woman.  \nIn order  to gain 1 life year, on average a woman receives 4 positive screening test result with \n5-yearly cytology, 6 with 3- yearly cytology, 2 2 with 3 -yearly HPV with dual  triage, 9 0 with \nbiennial HPV with dual  triage, and 6 16 with annual cyt ology  with triage . All other screening \nstrategies are dominated.  \n5-yearly or 3-yearly HPV with dual  triage seem s to result in a good balance between benefits \n(gain in life expectancy) and harms associated with positive test results.   \n54 Table 14. Sensitivity analysis IHBR (positive tests/LYG): decreased cytology sensitivity.  \nCytology sensitivity  55.4% for \nCIN3+  68.5% for \nCIN3+  \nStrategy  IHBR \n(Positive \ntests/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Interval l 2J Alter 25J -30J; Alter > 30J, Intervall 5J  4 3 \n17. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  \n 6 Dom  \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  \n Dom  8 \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  \n 22 24 \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J  bis \n30J, Intervall 2J  \n 90 82 \n15. LBC / HPV Tr iage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  \n 616 363 \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n55 Figure 15. Sensitivity analysis IHBR (positive tests/LYG): decreased sensitivity values for \ncytology  \n \n \nSensitivity and Specificity of Colposcopy  \nIn mul ti-way sensitivity analyses colposcopy accuracy data were varied [specificity of 0.566, \nand sensitivity of 0.760 for CIN1/CIN2 and 0.983 for CIN3+].  \nTable 15 shows the incremental harm -benefit ratios (in positive tests / LYG) for the non -\ndominated strategies, when alternative colposcopy accuracy data are used. Figure 16 shows \nthe benefit- harm frontier for the scenario with alternative sensitivity and specificity values \nfor colposcopy.  \nIn order to gain 1 life year, on average a woman receives 3  positive screening test results \nwith 5 -yearly cytology, 8 with 5- yearly HPV with dual  triage, 21 with 3 -yearly HPV with dual  \ntriage, 68 with biennial HPV with dual  triage, and 275 with annual cytology with  triage. All \nother screening strategies are dominated.  \n \n56 5-yearly or 3-yearly HPV with dual  triage seem s to result in a good balance between benefits \n(gain in life expectancy) and harms associated with positive test results.  \nTable 15. Sensitivity analysis IHBR (positive tests/LYG): alternative sensitivity and \nspecificity values for colposcopy.  \nCytology sensitivity  Cantor \n2008  Mitchell \n1998  \nStrategy  IHBR \n(Positive \ntests/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  3 3 \n33. HPV / p16/Ki -67 Triage: Alter >30J, In tervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  8 8 \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap:  Alter 25J bis \n30J, Intervall 2J  21 24 \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  68 82 \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  275 363 \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n57 Figure 16. Sensitivity analysis IHBR (positive tests/LYG): alternative sensitivity and \nspecificity values for colposcopy  \n \n \nScreening Adherence  \nTable 16 shows the incremental harm -benefit ratios (in positive tests / LYG) for the non -\ndominated strategies, if the screening adherence rate is increased to 100%.  \nFigure 17 shows the relation between total number of screen -positives and t he gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receives 4 positive screening test result with \n5-yearly cytology, 18 with 5- yearly HPV with dual stain , 182 with triennial HPV with dual \nstain , 1,393with biennial HPV with dual stain , and 7,467 with biennial HPV and  cytology \ncotesting . All other screening strategies are dominated.  \n \n58 For women with full screening adherence , 5-yearly HPV with dual stain triage seem to result \nin a good balance between benefits (gain in life expectancy) and harms associated with \npositive test results.  \nTable 16. Sensitivity analysis IHBR (positive tests/LYG): 100% screening adherence.  \nScreening adher ence rate  100%  70-80%  \nStrategy  IHBR \n(Positive \ntests/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  4 3 \n33. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  18 8 \n32. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J 26. HPV / Conv. Pap-Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; \nPap: Alter 25J bis 30J, Interval l 2J 182 24 \n31. HPV / p16/Ki -67 Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J 25. HPV / Conv. Pap-Triage: Alter > 30J, Intervall  HPV - 2J, HPV+ 1J ; \nPap: Alter 25J bis 30J, Intervall 2J  1393  82 \n15. LBC / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; A lter > 30J, Intervall 1J 19. \nHPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  Dom  363 \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  7467  Dom  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n59 Figure 17. Sensitivity analy sis IHBR (positive tests/LYG): 100% screening adherence.  \n \n \n6.1.2 Colposcopies  \nSensitivity of Cytology  \nTable 17 shows the incremental harm -benefit ratios (in colposcopies / LYG) for the non -\ndominated strategies, if the test sensitivity values for the Pap cytology test are varied \naccording to the lower 95% CIs.  \nFigure 18 shows the relation between total number of colposcopies and the gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life y ear, on average a woman receives 3 colposcopies with 5 -yearly HPV \n+cytology cotesting, 11 with 3 -yearly HPV +cytology cotesting, 40 with 2 -yearly HPV \n+cytology cotesting, 120 with current annual Pap screening, 3,136 with annual cytology with \n \n60 dual triage, and 4,603 with annual cytology with HPV triage. All other screening strategies \nare dominated.  \nTriennial or biennial HPV plus cytology cotesting seem to result in a good balance between \nbenefits (gain in life expectancy) and harms associated with colposcopie s. \nTable 17. Sensitivity analysis IHBR (colposcopies/LYG): decreased cytology sensitivity.  \nCytology sensitivity  55.4% for \nCIN3+  68.5% for \nCIN3+  \nStrategy  IHBR \n(Colposcop\nies/LYG)  Base case  \n1. Kein Screening    \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 5J  Dom  3 \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  3 3 \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, I ntervall 2J    11 11 \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  40 35 \n2. Conv. Pap: Alter 20J, Intervall 1J  120 207 \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nInterv all 1J  3,136  728 \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  4,603  147,397  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gaine d, Dom: dominated.  \n  \n61 Figure 18. Sensitivity analysis IHBR (colposcopies/LYG): decreased sensitivity values for \ncytology  \n \n \nSensitivity and Specificity of Colposcopy  \nTable 18 shows the incremental harm -benef it ratios (in colposcopies / LYG) for the non -\ndominated strategies, if alternative test accuracy data for colposcopy are applied.  \nFigure 19 shows the relation between total number of colposcopies and the gain in \nremaining life exp ectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receives 3 colposcopies with 5 -yearly HPV \n+cytology cotesting, 10 with 3 -yearly HPV +cytology cotesting, 30 with 2 -yearly HPV \n+cytology cotesting, 140 with current annual Pap scr eening, 652 with annual cytology with \ndual triage, and 147,193 with annual cytology with HPV triage. All other screening strategies \nare dominated.  \n \n62 Triennial or biennial HPV plus  cytology cotesting seem to result in a good balance between \nbenefits (gain in life expectancy) and harms associated with colposcopies.  \nTable 18. Sensitivity analysis IHBR (colposcopies/LYG): alternative sensitivity and \nspecificity values for colposcopy.  \nColposcopy accuracy  Cantor \n2008  Mitchell \n1998  \nStrategy  IHBR \n(Colposcop\nies/LYG)  Base case  \n1. Kein Screening    \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 5J  Dom  3 \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  3 3 \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  10 11 \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  30 35 \n2. Conv. Pap: Alter 20J, Intervall 1J  140 207 \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 1J  652 728 \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  147,193  147,397  \nHPV: human papilloma virus test, Pap: Papanicolaou cyto logy test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n63 Figure 19. Sensitivity analysis IHBR (colposcopies/LYG): alternative sensitivity and \nspecificity values for colposcopy.  \n \n \nScreening Adherence  \nTable 19 shows the incremental harm -benefit ratios (in colposcopies / LYG) for the non -\ndominated strategies, if the screening adherence is increased to 100%.  \nFigure 20 shows the relation between t otal number of colposcopies and the gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receives 3 colposcopies with 5 -yearly \ncytology with dual stain triage, 5 with 5-yearly HPV with cytology triage, 138  colposcopies \nwith biennial HPV and cytology triage, 312 with 3 -yearly cytology with HPV triage, 434 \ncolposcopies with current annual Pap screening. All other screening strategies are \ndominated.  \n \n64 For women with full screening adhere nce, 5-yearly HPV plus cytology cotesting seem to \nresult in a good  balance between benefits (gain in life expectancy) and harms associated \nwith colposcopies.  \nTable 19. Sensitivity analysis IHBR (colposcopies/LYG): decreased cytology sensitivity.  \nCytology sensitivity  100%  70-80%  \nStrategy  IHBR \n(Colposcop\nies/LYG)  Base case  \n1. Kein Screening    \n6. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 5J  3 3 \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  5 Dom  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  Dom  3 \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  138 Dom  \n20. HPV + Conv. Pap Cotesting: Alte r >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  Dom  11 \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  Dom  35 \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  312 Dom  \n2. Conv. Pap: Alter 20J, Intervall 1J  434 207 \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 1J  Dom  728 \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  Dom  147,397  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n65 Figure 20. Sensitivity analysis IHBR (colposcopies/LYG): 100% screening  adherence  \n \n \n6.1.3 Conization < CIN3  \nSensitivity of Cytology  \nTable 20 shows the incremental harm -benefit ratios (in conizations < CIN3 / LYG) for the \nnon-dominated strategies, when test sensitivity values for the Pap cytology test are varied \naccording to the lower 95% CIs.  \nFigure 21 shows the relation between total number of conizations < CIN3 and the gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receiv es 0.3 conizations < CIN3 with 5 -yearly \nor 3-yearly cytology, 0.9 conizations < CIN3 with 3 -yearly HPV with cytology triage, 1.0 \nconizations < CIN3 with 3 -yearly HPV -  cytology cotesting, 1.9 with bienn ial HPV with \n \n66 cytology triage, and 3.8 conizations < CI N3 with annual cytology in her lifetime. All other \nscreening strategies are dominated.  \nHPV plus cytolog y cotesting or HPV with cytology triage every 5 or 3 years seem to result in a \ngood balance between benefits (gain in life expectancy) and harms associated with p ositive \ntest results.  \nTable 20. Sensitivity analysis IHBR (conizations < CIN3/LYG): decreased cytology sensitivity.  \nCytology sensitivity  55.4% for \nCIN3+  68.5% for \nCIN3+  \nStrategy  IHBR \n(conization \n< CIN3 / \nLYG)  Base case  \n1. Kein Scr eening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  0.3 0.3 \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  Dom  0.4 \n21. HPV + Conv. Pap Cotestin g: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  Dom  0.5 \n9. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 3J  0.3 Dom  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J  bis \n30J, Intervall 2Jbis 30J, Intervall 2J  0.9 0.9 \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  1.0 1.0 \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  Dom  1.7 \n3. Conv. Pa p / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 1J  Dom  4.2 \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  1.9 Dom  \n7. Conv. Pap / HPV Triage: Alter 25J, Interv all 2J Alter 25J -30J; Alter > 30J, Intervall 1J  3.8 Dom  \n   \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n67 Figure 21. Sensitiv ity analysis IHBR (conizations < CIN3/LYG): decreased sensitivity values \nfor cytology.  \n \n \nSensitivity and Specificity of Colposcopy  \nIn multi -way sensitivity analyses colposcopy accuracy data were varied [specificity of 0.566, \nand sensitivity of 0.760 for C IN1/CIN2 and 0.983 for CIN3+].  \nTable 21 shows the incremental harm -benefit ratios (in conizations < CIN3 / LYG) for the \nnon-dominated strategies, when alternative data for the accuracy of colposcopy are applied.  \n \n68 Figure 22 shows the relation between total number of conizations < CIN3 and the gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receives 0.2 conizations < CIN3 with 5 -yearly \ncytology, 0.3 con izations < CIN3 with 5 -yearly HPV with cytology triage, 0.5 conizations < \nCIN3 with 5 -yearly HPV -  cytology cotesting, 0.7 with tri ennial cytology with HPV triage, 0. 8 \nconizations < CIN3 with 3 -yearly HPV -  cytology cotesting, 1.5 with b iennial HPV  - cytology  \ncotes ting, 4.1 conizations < CIN3 with annual cytology + dual triage and 1 4.9 with annual \ncytology with HPV triage. All other screening strategies are dominated.  \nHPV plus cytolog y cotesting or HPV with cytology triage every 5 or 3 years seem to result in a \ngood balance between benefits ( gain in life expectancy) and harms associated with positive \ntest results.  \nTable 21. Sensitivity analysis IHBR (conizations < CIN3/LYG): alternative sensitivity and \nspecificity values for colposcopy.  \nColposcopy accuracy  Cantor \n2008  Mitchell \n1998  \nStrategy  IHBR \n(conization \n< CIN3 / \nLYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  0.2 0.3 \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  0.3 0.4 \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  0.5 0.5 \n8. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 2J  0.7 Dom  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2Jbis 30J, Intervall 2J  Dom  0.9 \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  0.8 1.0 \n22. HPV + LBC Cotesting: Alt er >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  1.5 1.7 \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 1J  4.1 4.2 \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Inter vall 1J  14.9  Dom  \n   \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n  \n69 Figure 22. Sensitivity analysis: alternative sensitivity a nd specificity values for colposcopy  \n \n \nScreening Adherence  \nTable 22 shows the incremental harm -benefit ratios (in conizations < CIN3 / LYG) for the \nnon-dominated strategies, if the screening adherence is increased to 100%.  \nFigure 23 shows the relation between total number of conizations < CIN3 and the gain in \nremaining life expectancy per screened woman.  \nIn order to gain 1 life year, on average a woman receives 0.3 conizations < CIN3 with 5 -yearly \ncytol ogy, 0.7 conizations < CIN3 with 5 -yearly HPV with cytology triage, 1.0 conizations < \n \n70 CIN3 with 5 -yearly HPV -  cytology cotesting, 4.0 with 3 -yearly HPV -  cytology cotesting, and \n18.1 with 2- yearly HPV -  cytology cotesting. All other screening strategies a re dominated.  \nIn women with full screening adherence, 5-yearly HPV with cytology triage or cotesting seem \nto result in a good balance between benefits (gain in life expectancy) and harms associated \nwith positive test results.  \nTable 22. Sensitivity analysis IHBR (conizatio ns < CIN3/LYG): 100% screening adherence.  \nScreening adherence  100%  70-80%  \nStrategy  IHBR \n(conization \n< CIN3 / \nLYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  0.3 0.3 \n27. HPV  / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  0.7 0.4 \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  1.0 0.5 \n26. HPV / Conv. Pap -Triage: Alter >30J, Interval l  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2Jbis 30J, Intervall 2J  Dom  0.9 \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  4.0 1.0 \n22. HPV + LBC Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  18.1  1.7 \n3. Conv. Pap / p16/Ki -67 Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, \nIntervall 1J  Dom  4.2 \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life yea rs gained, Dom: dominated.  \n  \n71 Figure 23. Sensitivity analysis IHBR (conizations < CIN3/LYG): 100% screening adherence  \n \n \n6.2 Incremental Cost -Effectiveness  \nIn general, the model results for the cost- effectiveness analyses were very robus t when \nselected parameters were varied across plausible ranges in sensitivity analyses . Triennial \nHPV screening with cytology triage may be considered as cost -effective even when the \naccuracy of cytology or colposcopy is reduced or the cancer treatment cos ts are increased. \nIn women attending the screening program regularly (100% adherence) , triennial HPV \nscreening with cytology triage remained  cost-effective.  \n \n72 Cytology Sensitivity  \nIn multi -way sensitivity analyses, Pap cytology sensitivity values were varied  using the lower \n[44.8% ( CIN1), 62.5% (CIN2), 55.4% (CIN3+)] 95% confidence interval limits. All strategies \nthat have Pap cytology as a primary screening test or as a follow -up test are influenced \nsimultaneously in this analysis.  \nTable 23 shows the incremental cost -effectiveness ratios (in Euro / LYG) for the non -\ndominated strategies, if the test sensitivity values for the Pap cytology test are varied \naccording to the lower 95% CIs. Figure 24 shows the cos t-effectiveness frontiers for the \nscenario with reduced (lower limit) test sensitivity values for cytology.  \nIf the sensitivity of cytology is as low as the lower 95% CI values, the strategy \u201c2 -yearly HPV +  \nPap cotesting\u201d is not dominated anymore and is p ositioned  on the cost -effectiveness \nfrontier, whereas, the strategy \u201cannual cytology with HPV triage\u201d is dominated.  \nIn the scenario with lower test sensitivity values for cytology, triennial HPV / Pap triage \nremains a cost-effective screening option.  \nTable 23. Sensitivity analysis: decreased cytology sensitivity.  \nCytology sensitivity  55.4% for \nCIN3+  68.5% for \nCIN3+  \nStrategy  ICER \n(Euro/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Al ter > 30J, Intervall 5J  4,588  4,212  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  5,636  9,210  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Inter vall 2J  30,383  30,599  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  106,851  107,715  \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  507,682  Dom  \n7. Con v. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  Dom  531,379  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated.   \n73 Figure 24. Sensitivity analysis: decreased sensitivity values for cytology  \n \n \nColposcopy Sensitivity and Specificity  \nIn multi -way sensitivity analyses colposcopy accuracy data were varied [specificity of 0.566, \nand sensitivity of 0.760 fo r CIN1/CIN2 and 0.983 for CIN3+].  \nTable 24 shows the incremental cost -effectiveness ratios (in Euro / LYG) for the non -\ndominated strategies, when alternative colposcopy accuracy data are used. Figure 25 shows \nthe cost- effectiveness frontier for the scenario with alternative sensitivity and specificity \nvalues for colposcopy.  \nThe ranking remained the same with the variation of colposcopy accuracy values. The ICERs \nof the different strategies changed only slightly. In the scenario with alternative sensitivity \nand specificity values for colposcopy , triennial HPV / Pap triage remains a  cost-effective \nscreening option.  \n \n74 Table 24. Sensitivity analysis: alternative colposcopy accuracy data.  \nColposcopy accuracy  Cantor \n2008  Mitchell \n1998  \nStrategy  ICER \n(Euro/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  4,349  4,212  \n27. HPV / Conv. Pap -Triage: Alter >30J, Inter vall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  8,597  9,210  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  26,201  30,599  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  88,251  107,715  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  407,378  531,379  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost-\neffectiveness ratio, LYG: life years gained, Dom: dominated.  \n \nFigure 25. Sensitivity analysis: alternative sensitivity and specificity values for colposcopy  \n \n \n \n75 Screening Adherence  \nTable 25 shows the incremental cost -effectiveness ratios (in Euro / LYG) for the non -\ndominated strategies, if the screening adherence is increased to 100%. In general, the \nscreening adherence rate was applied to all strategies and all screening intervals \nsimultaneously. Figure 26 shows the cost- effectiveness frontier  for the analysis with 100% \nscreening adherence rate.  \nPredicted model outcomes are sensitive to screening adherence variation. With increasing \nadherence rate, ICERs increased for all scre ening strategies .  \nThe corresponding ICERs  are 5,232 Euro/LYG for 5- yearly screening with cytology and HPV \ntriage, 19,593 Euro/LYG for 5- yearly screening with HPV plus cytology triage, 112,594 \nEuro/LYG for 5 -yearly screening with HPV+Pap cotesting, 220,227  Euro/LYG for 3 -yearly HPV \nwith cytology triage, 598,886 Euro/LYG for 3 -yearly HPV+Pap cotesting, 2,028,149 Euro/LYG \nfor bienn ial HPV with cytology triage, and 3,016,040 Euro/LYG for bienn ial HPV+Pap \ncotesting.  \nIn women certainly attending with a screening adherence of 100%, 2 -yearly and even 3-\nyearly screening programs are highly likely to be no more cost -effective, and 5-yearly HPV \nscreening with cytology triage can be considered as  a cost effective option in this scenario.  \nTable 25. Sensitivity analysis: 100% screening adherence.  \nScree ning adherence  100%  70-80%  \nStrategy  ICER \n(Euro/LYG)  Base case  \n   \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  5,232  4,212  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, H PV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  19,593  9,210  \n21. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 5J; Pap: Alter 25J -30J, Intervall 2J  112,594  Dom  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  220,227  30,599  \n20. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 3J; Pap: Alter 25J -30J, Intervall 2J  598,886  Dom  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  2,028,149  107,71 5 \n19. HPV + Conv. Pap Cotesting: Alter >30J, Intervall 2J; Pap: Alter 25J -30J, Intervall 2J  3,016,040  Dom  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  Dom  531,379  \nHPV: human papilloma virus test, Pap: Papan icolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years gained, Dom: dominated   \n76  \nFigure 26. Sensitivity analysis: 100% screening adherence.  \n \n \nCancer Treatment Costs  \nTable 24 show s the incremental cost -effectiveness ratios (in Euro / LYG) for the non -\ndominated strategies, when alternative colposcopy accuracy data are used. Figure 25 shows \nthe cost- effectiveness frontiers for the scenario with alternative s ensitivity and specificity \nvalues for colposcopy.  \nThe ranking remained the same with the variation of cancer treatment costs. The ICERs of \nthe different strategies decreased. However , in the scenario with increased cancer \ntreatment costs , triennial HPV with cytology triage remains the cost -effective screening \noption.  \n \n77 Table 26. Sensitivity analysis: cancer treatment costs increased to 4 -fold of the base case \nvalues.  \nCancer treatment costs (Euro) for FIGO stage 1 - 4. 18,715 - \n29,387  4,679 -\n7,347  \nStrategy  ICER \n(Euro/LYG)  Base case  \n1. Kein Screening    \n10. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 5J  4,349  4,212  \n27. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 5J, HPV+ 1J ; Pap: Alter 25J bi s \n30J, Intervall 2J  8,597  9,210  \n26. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 3J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Intervall 2J  26,201  30,599  \n25. HPV / Conv. Pap -Triage: Alter >30J, Intervall  HPV - 2J, HPV+ 1J ; Pap: Alter 25J bis \n30J, Interva ll 2J 88,251  107,715  \n7. Conv. Pap / HPV Triage: Alter 25J, Intervall 2J Alter 25J -30J; Alter > 30J, Intervall 1J  407,378  531,379  \nHPV: human papilloma virus test, Pap: Papanicolaou cytology test, ICER: incremental cost -\neffectiveness ratio, LYG: life years  gained, Dom: dominated.  \n \nFigure 27. Sensitivity analysis: increased cancer treatment costs  \n \n \n78 7 Discussion of Model Features and Limitations  \nThis evidence report describes the decision -analytic study  for cervical cancer screening to \nevaluate the benefits, harms and cost -effectiveness of different screening strategies in order \nto inform the development of the German evidence -based S3 clinical g uideline  \u201cPrevention \nof Cervical Cancer \u201d. \nWe performed evidence- based benefit -harm analys es and cost -effective ness analyse s \ncomparing several cervical cancer screening strategies . In order to synthesize all best \navailable evidence, we performed a decision analysis incorporating evidence on \nepidemiologic parameters, benefits, harms and costs.  The decision -analytic model is \ndesigned to be applied in the context of comparative effectiveness analysis and economic evaluation analysis in order to inform evidence -based clinical guideline development. We \nperformed comprehensive sensitivity analyses to eval uate the uncertainty of our results.  \nWe followed international guidelines  of decision -analytic modeling (2-6, 7 ) . Nevertheless, a s \nall decision -analytic modeling studies, this evaluation informing a clinical guid eline has \nseveral limitations.  \nFirst, a published and validated model has been adapted to the context of the S3 guideline, \nand therefore, it was not possible to include all aspects covered or discussed in the S3 \nguideline into the decision -analytic framew ork of this analysis. For example, we did not \nperform formal decision analyses on the optimization of the length of the screening interval \nfor women in the age of 25 -30 years.  \nSecond , there were no empirical quality -of-life data, which could have been addi tionally \nimplemented into the model. As such, long- term effectiveness was based on life expectancy \n(measured in life years) instead of quality -adjusted life expectancy  (measured in quality -\nadjusted life years, QALYs) . Since screening results in a relatively small average gain in life \nexpectancy, changes in quality -of-life due to psychological distress associated with the \ncommunication of screening results or adverse events of pre -cancer treatment may \nsignificantly affect the estimated harm -benefit ratios an d/or cost-effectiveness ratios  (46, \n47).  \nThird , due to a lack of detailed individual data, age -specific adherence rates were assumed \nto equal average age-specific adherence rates in every screening round independe nt of prior \nscreening history. No individual -level data on more complex adherence patterns were  \n79 available. In addition, as no information was available on how adherence may change with \nincreasing screening interval, we used the  same adherence rate for all strategies and \nintervals. However, health insurance data on screening adherence show much lower \nscreening adherenc e within one year compared to a three -year time horizon. As we used \n70% -80% screening adherence for all strategies in the analyses, annual screening effects, \nharms, and costs are likely over estimated, and cannot be compared with real data observed \nin current annual cytology screening in Germany. In addition, compliance with follow -up of \nabnormal screening results, diagnosis and treatment was con sidered to be 100%, which may \nbe not the situation in real life.  \nFourth , test sensitivity and specificity data for primary screening test were based upon \nresults from meta -analysis including data from randomized clinical trials. However, \nsensitivity and sp ecificity in real world settings may be significantly reduced, particularly  for \ncytology.  In addition, for lesions with specific morphologic conditions, test performance of \nrepeated tests may be lower than for the first test. As this aspect affects cytolog y-based \nstrategies more than HPV -based strategies, it is likely that particularly the benefits of \ncytology -based screening strategies with 1 -year or 2 -year screening intervals are \noverestimated, and in reality result in a worse benefit -harm balance and cos t-effectivenes s \nratios  than reported in the base- case analyses. We have considered this aspect in a \nsensitivity analysis lowering test performance s. \nFifth , we assumed no false -positive biopsy results , and therefore, no false -positive \nconizations ( i.e., conization in women with no lesion, but a positive test result). However, \nstudies comparing cone biopsies to biopsy results are showing false positive rates. In addition, we assumed only conizations in women with CIN 1 if the lesion progressed to CIN \n2, but n ot if the lesion persisted without progression. Therefore, our analyses results on \nharms (total conizations and conizations below CIN3) may underestimate harm in all \nstrategies.  \nSixth , our decision model did not consider heterogeneity of the population wi th respect to \ndifferent HPV types and did not include separate states for women treated for precancerous \nlesions . This leads to a bias in the model against HPV screening  (48-50). \nSeventh , only direct medical costs from the perspective of the health care system were \nconsidered  and i npatient costs were likely slightly underestimated . Therefore, HPV screening \nmay be slightly more cost effective as shown in our analyses.   \n80 Eighth , model parameters have been calibrated to specific studies in a German population \nwith limited sample size (42) . Alternatively, larger samples used for European populations \ncould be used, in particular, when HPV vaccination started to show effects.  For ins tance, the \nInternational Agency for Research on Cancer ( IARC) und th e Information Centre on HPV and \nCancer (ICO)  are currently preparing a European database, which also includes age -specific \nprevalences form larger observational studies.   \nOverall, the comp rehensive sensitivity analyses  performed in this study showed robust \nresults. Although numbers changed, the overal l implications with respect to the guiding \ninformation for the clinical S3 guideline did not change substantially.  \nFuture research is needed t o acquire evidence -based information on individual -level \nadherence patterns and the impact of screening results on quality -of-life. In addition, as the \nintroduction of HPV vaccination may result in lower future HPV incidence  and consequently \nlower prevalen ce of CIN and cervical cancer,  this may also change the accuracy of screening \ntests for detecting cervical lesions . Further modelling studies including long- term data from \nvaccinated women in Germany are recommended  to fill this research gap . \n \n   \n81 8 References  \n \n1. Siebert U. When should decision- analytic modeling be used in the economic evaluation \nof health care? [Editorial]. European Journal of Health Economics. 2003;4(3):143 -50. \n2. Caro JJ, Briggs AH, Siebert U, Kuntz KM, on behalf of the ISPOR -SMDM Modeling Good \nResearch Practices Task Force. Modeling Good Research Practices -  Overview: A \nReport of the ISPOR -SMDM Modeling Good Research Practices Task Force - 1. Medical \nDecision Making. 2012;32(5):667- 77. \n3. Caro JJ, Briggs AH, Siebert U, Kuntz KM, on behalf of the ISPOR -SMDM Modeling Good \nResearch Practices Task Force. Modeling Good Research Practices -  Overview: A \nReport of the ISPOR -SMDM Modeling Good Research Practices Task Force - 1. Value in \nHealth. 2012;15:796- 803. \n4. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State- Transition \nModeling: A Report of the ISPOR -SMDM Modeling Good Research Practices Task \nForce -3. Value in Health. 2012;15:812- 20. \n5. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. S tate-Transition \nModeling: A Report of the ISPOR -SMDM Modeling Good Research Practices Task Force \n-3. Medical Decision Making. 2012;32(5):690- 700. \n6. Drummond MF, Schwartz JS, Jonsson B, Luce BR, Neumann PJ, Siebert U, et al. Key \nprinciples for the improved  conduct of health technology assessments for resource \nallocation decisions. International journal of technology assessment in health care. \n2008;24(3):244- 58. \n7. Drummond M, Schwartz JS, Jonsson B, Luce B, Neumann P, Siebert U, et al. Response from the aut hors of \"Key principles for the improved conduct of health technology \nassessments for resource allocation decisions\". International journal of technology \nassessment in health care. 2008;24(3):367- 8. \n8. Siebert U, Muth C, Sroczynski G, Velasco- Garrido M, Gerhardus A, Gibis B, editors. \nD\u00fcnnschichtpr\u00e4parationen und computergest\u00fctzte Untersuchung von Zervixabstrichen im Rahmen der Krebsfr\u00fcherkennung \u2013  Medizinische Effektivit\u00e4t, \ngesundheits\u00f6konomische Evaluation und systematische Entscheidungsanalyse. Schriftenr eihe Health Technology Assessment Bd. 35. St. Augustin: Asgard; 2004.  \n9. Siebert U, Sroczynski G, Hil lemanns P, Engel J, Stabenow R, Stegmaier C, et al. The \nGerman cervical cancer screening model: development and validation of a decision- \n82 analytic model for  cervical cancer screening in Germany. Eur J Public Health. \n2006;16(2):185- 92. \n10. Sroczynski G, Schnell -Inderst P, M\u00fchlberger N, Lang K, Aidelsburger P, Wasem J, et al. \nEntscheidungsanalytische Modellierung zur Evaluation der Langzeit -Effektivit\u00e4t und \nKosten-Effektivit\u00e4t des Einsatzes der HPV -DNA -Diagnostik im Rahmen der \nZervixkarzinomfr\u00fcherkennung in Deutschland. Schriftenreihe Health Technology \nAssessment Bd. 98. K\u00f6ln: Deutsches Institut f\u00fcr Medizinische Dokumentation und \nInformation (DIMDI), Bundesminis terium f\u00fcr Gesundheit (BMG); 2010. 1- 127 p.  \n11. Sroczynski G, Schnell -Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, et al. \nCost-effectiveness of primary HPV screening for cervical cancer in Germany -  a decision \nanalysis. Eur J Cancer. 2011;47(1 1):1633- 46. \n12. Institute for Quality and Efficiency in Health Care (IQWiG). General Methods (Version 4.2). 2015. Available from: https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204- 2.pdf\n. \n13. Bearman DM, MacMillan JP, Creasman WT. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol. 1987;69(2):151- 5. \n14. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical \nscreening practice in the UK: results from a modelling study. Br J Cancer. \n2004;91(3):530- 6. \n15. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. \nPersistence of type- specific hum an papillomavirus infection among cytologically normal \nwomen. J Infect Dis. 1994;169(2):235- 40. \n16. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal \npapillomavirus infection in young women. N Engl J Med. 1998;338(7):423- 8. \n17. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272- 8. \n18. Legood R, G ray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost \neffectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ. 2006;332(7533):79- 85.  \n83 19. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y, et al. Benefits \nand Costs of Using HPV Testing to Screen for Cervical Cancer. JAMA. \n2002;287(18):2372- 81. \n20. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural \nhistory of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132(2):277- 84. \n21. Munoz N, Kato I, Bosch FX, Eluf -Neto J, De Sanjose S, Ascunce N, et al. Risk factors for \nHPV DNA detection in middle- aged women. Sex Transm Dis. 1996;23(6):504- 10. \n22. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. American \nJournal of Epidemiology. 2000;151(12):1158- 71. \n23. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. Natural history of \ncervical human papillomavirus lesions does not substantiate the biologic relevance of the \nBethesda System. Obstet Gynecol. 1992;79(5 ( Pt 1)):675- 82. \n24. van Oortmarssen G J, Habbema JD. Epidemiological evidence for age- dependent \nregression of pre- invasive cervical cancer. Br J Cancer. 1991;64(3):559- 65. \n25. Vessey MP, Villard- Mackintosh L, McPherson K, Coulter A, Yeates D. The epidemiology \nof hysterectomy: findings in a lar ge cohort study. Br J Obstet Gynaecol. 1992;99(5):402-\n7. \n26. Sroczynski G, Schnell -Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, et al. \nDecision -analytic modeling to evaluate the long- term effectiveness and cost -\neffectiveness of HPV -DNA testing  in primary cervical cancer screening in Germany. \nGMS Health Technol Assess. 2010;6:Doc05.  \n27. Statistisches Bundesamt (Destatis). Sterbetafel Deutschland 2009/2011. \nhttps://wwwdestatisde/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Ta\nbellen/SterbetafelDeutschlandhtml;jsessionid=8207CE0695C17A418CB15696F6468500\ncae1 . 2014.  \n28. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J \nEpidemiol. 2000;151(12):1158- 71. \n29. Goldie SJ, Kim JJ, Wright TC. Cost -effec tiveness of human papillomavirus DNA testing \nfor cervical cancer screening in women aged 30 years or more. Obstetrics and \ngynecology. 2004;103(4):619- 31.  \n84 30. Kerek -Bodden H, Altenhofen L, Brenner G, Franke A. Durchf\u00fchrung einer \nversichertenbezogenen Unters uchung zur Inanspruchnahme der Fr\u00fcherkennung auf \nZervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von \nAbrechnungsdaten. Berlin: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in der Bundesrepublik Deutschland, 2008.  \n31. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding \nhuman papillomavirus testing in secondary prevention of cervical cancer. Vaccine. \n2012;30 Suppl 5:F88- 99. \n32. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer \nscreening. Int J Cancer. 2006;119(5):1095- 101. \n33. McCrory DC, Matchar DB. Evaluation of cervical cytology -  systematic review: Agency for \nHealth Care Research and Quality (AHRQ); 1999.  \n34. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow -up of cervical cytologic \nabnormalities: a systematic review. Ann Intern Med. 2000;132(10):810- 9. \n35. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke- L\u00fcthge A, Bergeron C, et al. \nTriaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki -67 Dual -stained cytology. Gynecologic Oncology. 2011;121(3):505- 9. \n36. Schmidt D, Bergeron C, Denton KJ, Ridder R, Group. ECCS. p16/ki -67 dual -stain \ncytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. \n2011;119(3):158- 66. \n37. Bergeron C, Giorgi -Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, et al. \nInformed Cytology for Triaging HPV -Positive Women: Substudy Nested in the NTCC \nRandomized Controlled Trial. J Natl Cancer Inst. 2015;107(2): dju423.  \n38. Mitchell MF, Sc hottenfeld D, Tortolero- Luna G, Cantor SB, Richards -Kortum R. \nColposcopy for the diagnosis of squamous intraepithelial lesions: a meta- analysis. \nObstetrics and gynecology. 1998;91(4):626- 31. \n39. Statistisches Bundesamt. Mikrozensus Deutschland 2003. Available from: www.destatis.de\n. \n40. Statistisches Bundesamt. Mikrozensus Deutschland 2011. Available from: www.destatis.de\n.  \n85 41. Gilman J, Myatt M. EpiCalc 2000 (computer program). Version 1.02 ed: Brixton Books; \n1998.  \n42. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne- Heid R, Nindl I, et al. Screening for \nhigh-grade cervical intra- epithelial neoplasia and cancer by testing for high- risk HPV, \nroutine cytology or colposcopy. Int J C ancer. 2000;89(6):529- 34. \n43. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model \nparameter estimation and uncertainty analysis: a report of the ISPOR -SMDM Modeling \nGood Research Practices Task Force Working Group- 6. Medical decis ion making : an \ninternational journal of the Society for Medical Decision Making. 2012;32(5):722- 32. \n44. Cantor SB, Cardenas -Turanzas M, Cox DD, Atkinson EN, Nogueras -Gonzalez GM, Beck \nJR, et al. Accuracy of colposcopy in the diagnostic setting compared with the screening \nsetting. Obstetrics and gynecology. 2008;111(1):7- 14. \n45. Schwarzer R, Rochau U, Sav erno K, Jahn B, Bornschein B, Muehlberger N, et al. \nSystematic overview of cost -effectiveness thresholds in ten countries across four \ncontinents. Journal of Comparative Effectiveness Research. 2015:[in press].  \n46. Kyrgiou M, Koliopoulos G, Martin- Hirsch P,  Arbyn M, Prendiville W, Paraskevaidis E. \nObstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta- analysis. Lancet. 2006;367(9509):489- 98. \n47. McCaffery K, Waller J, Nazroo J, Wardl e J. Social and psychological impact of HPV \ntesting in cervical screening: a qualitative study. Sex Transm Infect. 2006;82(2):169- 74. \n48. Goldie SJ, Goldhaber -Fiebert JD, Garnett GP. Chapter 18: Public health policy for \ncervical cancer prevention: the role of decision science, economic evaluation, and \nmathematical modeling. Vaccine. 2006;24 Suppl 3:S3/155- 63. \n49. Goldie SJ, Kuntz KM. A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progression. M edical decision making : an \ninternational journal of the Society for Medical Decision Making. 2003;23(3):232- 41. \n50. Siebert U, Zietemann V, Sroczynski G. [Pharmacogenomics Bias -  Systematic Distortion \nof Study Results by Genetic Heterogeneity] GMS Health Technol Assess. 2008;4(Doc03):1- 7. \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}